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ABSTRACT 
 
 
Stumpf, Ashley. Comparison of Automated Hearing Testing Approaches for Outpatients 
Receiving Ototoxic Chemotherapy. Unpublished Doctor of Audiology Capstone 
Research Project, University of Northern Colorado, 2019. 
 
Detection of the highest audible frequency of hearing is used to monitor patients 
undergoing chemotherapy for ototoxic effects of pharmaceuticals.  The current study 
evaluated the feasibility of utilizing Creare’s (2016) wireless attenuated hearing test 
system (WAHTS) in two outpatient cancer treatment centers to administer automated 
hearing tests for the identification of the highest audible frequency.  Twenty cancer 
patients being treated with carboplatin and cisplatin were recruited for hearing testing and 
eight untrained nurses were recruited to operate the WAHTS.  Ambient noise 
measurements were taken in each treatment center before and after hearing testing and 
supported the validity of threshold measurements.  Listener participants completed two 
automated hearing tests: conventional high-frequency audiometry typically used to 
identify the sensitive region for ototoxicity (SRO) and a newly proposed fixed-level 
frequency test (FLFT; Fausti et al., 1999; Rieke et al., 2017).  The highest audible 
frequency (HAF) identified by each test method was compared using a 2-tailed Wilcoxon 
signed ranks test.  The HAF identified by each hearing test method (automated high 
frequency audiometry [AHFA] vs. FLFT) was not significantly different from each other.  
The FLFT was completed much faster (24.78 minutes for the AHFA versus 2.4 minutes 
for the FLFT).  Administering the FLFT during outpatient cancer treatment therapy 
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appeared to be a promising test method to potentially overcome current barriers in 
ototoxicity monitoring.  Future research should implement the WAHTS (Creare, 2016) 
technology in a more diverse assortment of chemotherapy treatment centers with a larger 
population of participants.  Use of the FLFT and AHFA would need to be evaluated as 
part of a clinical research study that would implement a full ototoxicity monitoring 
program.    
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CHAPTER I 
 
 
STATEMENT OF THE PROBLEM 
 
 
 Ototoxic hearing loss can occur when drugs or chemicals negatively interact with 
the structures in the auditory system, primarily in the cochlea.  This interaction causes 
damage that presents itself in the form of a hearing loss.  Certain pharmaceuticals have 
been documented to cause hearing loss.  Commonly prescribed ototoxic pharmaceuticals 
are aminoglycosides and platinum-based chemotherapeutics (Hawkins, 1976; Neuwelt et 
al., 1998).  Ototoxic hearing loss is a hearing loss that is potentially preventable with 
early detection and intervention.    
 A high frequency hearing loss is most commonly associated with ototoxic 
exposure, although not necessarily limited to that frequency alone.  With increased 
dosage and exposure, hearing loss is more likely to become more severe and affect lower 
frequency hearing abilities (Kopelman, Budnick, Sessions, Kramer, & Wong, 1988). 
When hearing loss begins to impact frequencies responsible for coding speech sounds, 
patients report social isolation, depression, and a reduced quality of life (Arlinger, 2003). 
Hearing loss has also been linked to cognitive decline in the elderly population (Lin et al., 
2013).  Prevention or rehabilitation of hearing loss due to ototoxicity is becoming a 
greater concern with the increased numbers of cancer survivors attributed to advances in 
medicine.   
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 The American Academy of Audiology (2009) recommended patients exposed to 
ototoxic pharmaceuticals be monitored for ototoxicity.  By monitoring for ototoxicity, 
more severe hearing loss might be prevented by modification of treatment regimens 
implemented by the physician.  If changes in treatment cannot be made, the patient might 
be referred for audiological intervention during the early stages of hearing loss.  Several 
approaches are accepted as effective ways of monitoring hearing changes but no matter 
the method, early detection is key in preventing a more severe hearing loss.  
 One approach accepted by the American Academy of Audiology (2009) relies 
upon high frequency audiometry.  This testing evaluates hearing thresholds at the 
frequency region most commonly affected by ototoxicity over time.  When hearing 
sensitivity decreases and meets certain criteria, an ototoxic shift in hearing is 
documented.  At this time, the physician can make an adjustment to treatment if 
indicated.  To reduce audiometric testing time, Fausti et al. (1999) determined a sensitive 
region for ototoxicity (SRO) worthy of focus.  The SRO approach monitors the highest 
frequency where a patient can hear at 100 dB SPL and the six adjacent frequencies as 
opposed to finding hearing thresholds at all frequencies from 250-20,000 Hz.  This 
shortens the test time and makes the monitoring potentially more cost efficient and 
efficient.  To calculate the SRO, baseline testing is obtained at all available test 
frequencies.  Moving forward, only the SRO is monitored.  
 Monitoring ceases to occur in many patients even though the implementation is 
well documented along with the negative effects of hearing loss.  The National 
Comprehensive Cancer Network’s (2003) guidelines, which are commonly followed by 
oncologists, do not suggest ototoxic monitoring, implying that many patients are not 
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receiving any audiologic treatment/management while receiving known ototoxic 
pharmaceuticals.  Possible reasons for why patients are not receiving audiologic services 
are related to patient and physician factors.  Patients are managing multiple appointments 
and potentially have reduced physical well-being due to the severity of the disease. 
Adding audiologic evaluations, which might add to the scheduling, transportation, and 
cost burdens, might not be a healthcare priority for the patient.  Physicians might be 
unaware of the importance of preventing hearing loss and preserving their patient’s 
communication abilities.  Therefore, patients are either not being referred for audiologic 
services or patients might be unable/unwilling to follow-up in a timely manner.   
 The purpose of the current study was to determine whether newly developed 
wireless automated hearing test system (WAHTS; Creare Inc., 2016) would make it 
possible for patients undergoing platinum-based cancer treatments to have their hearing 
status evaluated at the time of their chemotherapeutic treatment session.  The study also 
aimed to compare two audiometric testing procedures in terms of outcomes and time 
savings.  The first method was based upon the SRO approach implemented with Békésy 
(1947) method-of-adjustment threshold testing. The second, newer method uses a 
Békésy-like approach to quickly determine the highest audible frequency by sweeping 
pure-tones at 80 dB SPL; it is termed the fixed-level frequency test (FLFT).  
Implementation of this new technology and test protocols might potentially eliminate the 
need for patients to make multiple audiological appointments and coordinate schedules.   
It might also reduce the test time for patients who are easily fatigued due to disease and 
treatment demands.  If the research protocol was successful, it might be possible for more 
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patients to receive audiologic monitoring and prevention or rehabilitation of hearing loss 
due to ototoxicity.  
The following research questions and hypotheses guided this study: 
Q1  Is it feasible to implement the WAHTS (Creare Inc., 2016) technology in 
an outpatient cancer treatment center when operated by nurses? 
 
Q2  What are the ambient noise levels during chemotherapy in outpatient 
cancer centers? Is the attenuation of the WAHTS sufficient to allow for 
valid threshold testing in this environment? 
 
Q3  Is there a difference between the highest audible frequency identified  
using the FLFT test method compared to the automated high frequency  
audiometry (AHFA) obtained with the WAHTS? 
 
Q4  Is there a difference in test duration for the FLFT as compared to the 
AHFA test? 
 
H01  There will be no significant difference between the highest audible  
frequency detected when using the FLFT vs. the AHFA.  
 
H1  The FLFT test method will have significantly reduced test time when 
compared to the AHFA approach. 
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CHAPTER II 
 
 
REVIEW OF THE LITERATURE 
 
 
Introduction 
 
 Individuals diagnosed with cancer are often treated with chemotherapeutic drugs 
to save or prolong their lives.  When receiving these drugs, the body undergoes 
physiologic changes that are not isolated to the area affected by cancer.  The inner ear is 
an area commonly affected by these drugs and the pharmaceuticals are classified as 
ototoxic.  When inner ear structures are damaged due to the drug, hearing loss might 
occur, commonly in the high frequencies.  
 Hearing loss has been documented to cause social isolation, depression, and 
reduce the quality of life of the person directly affected and also negatively impacts 
communication partners (Arlinger, 2003).  Hearing loss is also linked to cognitive decline 
in the elderly population (Lin et al., 2013).  Individuals receiving chemotherapeutics are 
at an increased risk of hearing loss.  Therefore, it is important to provide an early 
detection and monitoring system to identify and track the progression of hearing loss.  
Once a hearing loss is detected, physicians might have options to adjust the 
administration or type of chemotherapy to help prevent further hearing loss.  It is often a 
delicate balance between the treatment needed for the life-threatening illness and the 
ototoxic dosage.  The American Speech-Language-Hearing Association (ASHA; 1994) 
and the American Academy of Audiology (2009) provided position statements on 
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ototoxic monitoring.  There are different modes of delivery of the monitoring programs.  
The following literature review explains the physiologic effects of chemotherapeutics on 
the ear, ototoxic monitoring using high frequency audiometry, and challenges present 
when implementing an ototoxic monitoring program.    
Auditory System Overview 
Normal Anatomy/Physiology 
The auditory system is comprised of the outer ear, middle ear, inner ear, auditory 
nerve, auditory brainstem, and auditory cortex.  The outer ear collects acoustic energy, 
which is transferred to the tympanic membrane.  The tympanic membrane separates the 
outer ear from the middle ear.  Vibration of the tympanic membrane forces the ossicles in 
the middle ear to vibrate.  In this process, acoustical energy is transformed into 
mechanical energy.  The most medial ossicle, the stapes, pushes on the round window of 
the cochlea in response to vibration.  The cochlea is located in the inner ear.  Pressure on 
the oval window causes movement of the fluid in the cochlea.  This fluid is produced by a 
structure in the cochlea called the stria vascularis.  This fluid movement causes the 
basilar membrane to be set into motion.  On top of the basilar membrane are the sensory 
cells of the cochlea, which is located in the organ of Corti.  These sensory cells are the 
inner and outer hair cells--one row of inner hair cells and three rows of outer hair cells. 
Located on top of the hair cells are stereocilia.  The outer hair cell’s main function is to 
amplify sound, whereas the inner hair cell’s function is to transmit the amplified signal 
electrochemically to the auditory nerve.  The basilar membrane is tonotopically 
organized.  The basal end of the cochlea codes high frequency information whereas the 
apex of the basilar membrane codes for low frequency information.  When the basilar 
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membrane is set into motion, the stereocilia shear causes an influx of calcium and 
potassium into the hair cell.  This influx of calcium and potassium allows for a 
neurotransmitter to be released into the synaptic junction, thus causing a signal to be sent 
along the auditory nerve and brainstem.  The signal makes its way to the auditory cortex 
where the brain can interpret it.  
Hearing Loss 
To have normal hearing, all of the structures in the auditory pathway need to be 
functioning properly.  Normal hearing ranges from -10 dB HL to 20 dB hearing level 
(HL) for adults in the conventional audiometric frequency range of 250-8000 Hz.  When 
hearing is within this range, the human cochlea has the ability to hear frequencies in 
human speech.  This allows for successful verbal communication.  When hearing 
thresholds are poorer than 20 dB HL, hearing at a distance, hearing soft sounds, or 
understanding speech in the presence of background noise becomes difficult.  The more 
severe the hearing loss, the greater the spoken communication difficulties.  
In the higher frequencies, thresholds are considered abnormal if they fall outside 
the -10-20 dB HL range as well.  Frank (1990) conducted a study with the main objective 
of determining high-frequency (8,000-16,000 Hz) thresholds (reference equivalent 
threshold sound pressure levels [RETSPLs]).  The second objective was to evaluate intra-
subject threshold variability at these frequencies.  Threshold testing was completed on 
100 individuals with normal hearing between 250 and 8,000Hz with an equal number of 
males and females.  Sennheiser HDA 200 circumaural earphones were used.  High 
frequency thresholds were subject to a three-factor analysis of variance.  The factors were 
test ear, test session, and gender.  No significance was shown for any factor.  The median 
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thresholds for each test session were similar across all frequencies.  As frequency 
increased, so did threshold.  Median threshold at 8,000 Hz was 18.2 dB sound pressure 
level (SPL); whereas at 16,000 Hz, the median threshold was 57.7 dB SPL.  Standard 
deviation also increased from 6.6 dB SPL at 8,000 Hz to 17.5 dB SPL at 16,000 Hz.  An 
analysis of variance (ANOVA) in R showed no significant difference in terms of the 
repeatability of high frequency thresholds.  Frank concluded that even though there was 
high intersubject variability for high frequency thresholds, RETSPLs could be used to set 
the output of the audiometers to 0 dB HL.  It was also important to note that between test 
sessions, there was minimal variation in threshold, signifying the successful application 
for serial monitoring of the high frequency thresholds (Frank, 1990).  At frequencies 
above 8,000 Hz, age affects thresholds (Osterhammel, 1977).  However, high frequencies 
in older adults can be used to obtain serial audiograms and monitor for changes even if 
thresholds are outside of the normal reference levels compared to young adults.  These 
outcomes are important since high-frequency audiometry might be useful to detect and 
monitor damage to the auditory system. 
Damage or malfunction in different areas of the auditory system accounts for 
different types of hearing loss.  If a problem exists in the outer or middle ear, acoustic 
energy might not be able to reach the sensory cells in the cochlea.  A hearing loss present 
due to outer or middle ear dysfunction is considered a conductive hearing loss.  In this 
case, the sensory cells of the auditory system are functioning properly but sound is 
reduced upon reaching the cochlea.  When damage occurs in the inner ear, it results in a 
sensory hearing loss.  This type of hearing loss is usually rehabilitated with hearing aids 
or cochlear implants and cannot be medically corrected in most cases.  If there is a 
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problem in the outer or middle ear and the inner ear, this is termed a mixed hearing loss. 
If the outer, middle, and inner ear are functioning normally, there could be a problem in 
the transmission of sound past the cochlea in the auditory nerve, brainstem, central 
auditory pathway, or cortex, causing a hearing loss termed “neural” hearing loss or 
“central” hearing loss.  Many factors could contribute to hearing loss including genetics, 
age, infection, and systematic disease.  Exposure to ototoxins such as noise, chemicals, 
and pharmaceuticals could also cause hearing loss.  
Ototoxicity 
Ototoxicity is a common side effect of some medications.  These pharmaceuticals 
cause damage in the cochlea, which results in a hearing loss.  For some medications, 
damage initially occurs in the basal end of the cochlea, causing hearing threshold shifts in 
the high frequency range.  However, damage is not limited to that cochlear location.  
Over time, auditory damage can progress toward the apical region of the cochlea, causing 
impairment of hearing in the mid-frequencies.  Ototoxic effects are not confined to the 
cochlea.  In some cases, ototoxicity can affect the vestibular system.  For the purposes of 
this manuscript, vestibulotoxicity is not discussed in detail.  
Multiple sources of ototoxic exposures can affect the cochlea, vestibular system, 
or both.  Due to life threatening conditions, patients must sometimes receive treatment 
through ototoxic sources.  Different classes of drugs and chemicals cause different 
symptoms from the ototoxicity.  A common source of ototoxicity is from 
chemotherapeutic drug exposure (chemotherapeutics).  This class of drugs is discussed in 
length in a later section.  Aminoglycosides are another well-documented class of 
medications known to be ototoxic.  Aminoglycosides were first found effective in 
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treating tuberculosis (Schatz & Waksman, 1944).  Due to low cost, aminoglycosides are 
the most common antibiotic used around the world (Schacht, 2007).  Aminoglycosides 
primarily affect outer hair cells, starting at the base of the cochlea and progressing to the 
apex with continued administration (Hawkins, 1976).   
 Loop diuretics have also been shown to have ototoxic effects; these drugs include 
ethacrynic acid, furosemide, bumetanide, and torsemide (Rybak, 2007).  Several loop 
diuretic studies conducted on rodents have shown ototoxic effects that were generally 
reversible (Green & Mirkin, 1981; Klinke & Mertens, 1988; Rybak, 1993).    
Commonly prescribed pharmaceutical agents can also be a source of ototoxicity 
including aspirin, anti-inflammatory drugs, quinine, and macrolides.  This class of drugs 
can cause a high frequency hearing loss along with tinnitus.  However, following 
cessation of the drug, the symptoms usually cease and no structural damage is done to the 
cochlea (Lonsbury-Martin, Martin, & Pettis, 2007). 
Chemical exposure can also cause ototoxic effects and make the hearing organ 
more susceptible to noise-induced hearing loss (Pouyatos & Pettis, 2007).  Carbon 
monoxide, cyanide, lead, mercury, manganese, ethyl benzene, xylene, trichloroethylene, 
and acrylonitrile are considered ototoxic chemicals.  Chemical solvents such as styrene 
and toluene are also ototoxic chemicals (Pouyatos & Pettis, 2007).  This manuscript 
focused on chemotherapeutics in terms of early detection of hearing loss and intervention 
to prevent hearing loss.     
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Chemotherapeutics 
Overview of Cancer Treatment 
  Cancer is often treated using chemotherapeutics.  In many patients diagnosed with 
cancer, the ototoxicity of the drug they are receiving is of minor concern in the context of 
life-threatening health issues.  In many cases, the only choice of treatment is an ototoxic 
drug.  Different dosages and types of chemotherapeutics are used to treat different 
cancers and different cancer stages.  However, not all chemotherapy drugs are known to 
cause hearing loss.  
 The purpose of chemotherapeutic drug therapy is to prevent cancer cells from 
proliferating, invading, and metastasizing (Rybak, Huang, & Campbell, 2007). 
Chemotherapeutics are classified based on their effect on the phases in the cell cycle 
(Skeel, 1999).  Phase-specific drugs are chemotherapeutics that are active against cells in 
a specific phase of the cell cycle including drugs that inhibit deoxyribonucleic acid 
synthesis.  There are also cell cycle-specific drugs that are only active when the cell is in 
cycle but are independent of the cell cycle’s phase.  The last classification is cell-cycle 
non-specific drugs.  In this classification, the drugs are effective whether the cells are in 
cycle or not.  Many chemotherapeutics are not bound to one classification; rather, 
multiple mechanisms are involved, causing multiple intracellular sites to be implicated 
(Rybak et al., 2007). 
Chemotherapeutic Agents and 
Associated Hearing Loss 
 
Cisplatin.  Cisplatin is a type of chemotherapy drug that was introduced in the 
1970s.  Some of the cancers commonly treated with cisplatin include germ cell, ovarian, 
endometrial, cervical, urothelial, head and neck, lung, and brain cancers (Boulikas & 
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Vougiouka, 2004; Sturgeon, 2004).  Cisplatin is systemically toxic (Hartmann & Lipp, 
2003), meaning its effects are not isolated to one area.  This leads to a potential for 
ototoxicity.  In fact, cisplatin is the most ototoxic platinum compound and the most 
ototoxic drug in clinical use (Hartmann & Lipp, 2003).   
Incidence of cisplatin ototoxicity varied within the research literature.  The range 
for ototoxicity from cisplatin is 40% to 60% (Bokemeyer et al., 1998; de Jongh et al., 
2003; Li, Womer, & Silber, 2004).  Different factors influence the risk for ototoxicity 
including dose regimen, administration, and location of cancer (Blakley, Gupta, Myers, & 
Schwan, 1994; Kopelman et al., 1988; Vermorken, Kapteijn, Hart, & Pinedo, 1983).  
Kopelman and colleagues (1988) monitored patients with advanced cancers 
receiving a high dosage of cisplatin (150 to 225 mg) by bolus administration.  A common 
dose is 50 mg (Rybak et al., 2007).  After one of two doses, all patients who previously 
had normal hearing failed to respond at 9,000 Hz and above (Kopelman et al., 1988), 
indicating the higher dosage of cisplatin dramatically increased the incidence of 
ototoxicity in these patients.  
Laurell and Jungnelius (1990) found the risk of ototoxicity was greater based on 
the amount of a single dose and not the cumulative dose.  Conversely, other researchers 
found the best predictor of ototoxic risk was more related to cumulative dose (Bokemeyer 
et al., 1998; Klis et al., 2002; Li et al., 2004).  Li et al. (2004) reported that when the 
cumulative dose reached 400 mg/m2, the risk of ototoxicity increased dramatically.  
Laurell and Jungnelius also found pre-existing hearing loss did not have an effect on 
ototoxic risk.  However, advanced age did increase the risk for ototoxicity with cisplatin.  
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Blakley et al. (1994) found the incidence of ototoxicity due to cisplatin increased 
when patients had decreased levels of red blood cells, hemoglobin, and serum albumin as 
a result of poor overall health.  Ototoxic risk was shown to be increased in guinea pigs 
when animals were exposed to high levels of noise 30 minutes prior to cisplatin (Laurell, 
1992). 
Hearing loss due to cisplatin ototoxicity initially occurs in frequencies higher than 
those traditionally tested in pure tone audiometry (250 Hz-8,000 Hz).  Kopelman and 
colleagues (1988) discovered the first signs of hearing loss occurred at 9,000 Hz and 
above.  After administration of a second high dose cisplatin (150-225 mg), hearing loss 
progressed into the lower frequencies (2,000 to 8,000 Hz).  However, the hearing loss did 
plateau at a moderate level hearing loss of 40 to 60 dB HL.  All participants also reported 
tinnitus (Kopelman et al., 1988).  
Laurell and Jungnelius (1990) monitored 54 patients receiving high dosages of 
cisplatin (100-120 mg).  Eighty-one percent of patients had at least 15 dB elevations in 
air conduction thresholds at one threshold and 10 dB shifts at three or more frequencies. 
Forty-one percent of these patients had deterioration of hearing in the speech frequencies 
(Laurell & Jungnelius, 1990).  Hearing loss associated with cisplatin ototoxicity is 
usually symmetric, bilateral, and permanent, especially when the hearing loss is in the 
profound range (Kopelman et al., 1988; Vermorken, Mangioni, & Van Oosterom, 1983). 
The hearing loss might also be progressive or sudden (Blakley & Myers, 1993).  
Structural changes have also been noted in the cochlea due to cisplatin therapy. 
Marco-Algarra, Basterra, and Marco (1985) observed in guinea pigs that the outer hair 
cells in the cochlea were more susceptible to damage compared to the inner hair cells. 
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Estrem, Babin, Ryu, and Moore (1981) also found that damage to the supporting and 
pillar cells occurred in guinea pig cochleas following cisplatin treatment.  Strauss et al. 
(1983) noted degeneration of spiral ganglion cells as well as cochlear neurons after 
examining the temporal bones of a patient with documented hearing loss who had frontal 
lobe astrocytoma and was treated with cisplatin.  
Carboplatin.  Carboplatin is another platinum compound commonly used to treat 
small cell lung, ovarian, head, and neck cancers (Bauer, Westhofen, & Kehrl, 1992; 
Gatzemeier et al., 1991; Gordon et al., 2002).  The greatest benefit of carboplatin over 
cisplatin is the overall lower neurotoxic effects (Cavaletti et al., 1997).  
Forty-four percent of pediatric patients receiving carboplatin along with 
hematopoietic stem cell transplantation expressed hearing loss (Punnett et al., 2004). 
Neuwelt and colleagues (1998) found 79% of patients had hearing loss due to ototoxicity 
when they were treated with carboplatin in combination with mannitol.  Contrarily, in the 
same study, Neuwelt and colleagues observed very little hearing loss when patients were 
treated with sodium thiosulfate following carboplatin treatment.   
 By using animal subjects, morphological changes in the cochlea were visible. 
Saito et al. (1989) found carboplatin-induced hearing loss caused damage to the outer hair 
cells; however, the inner hair cells remained undamaged in guinea pigs.  Wake, Takeno, 
Ibrahim, Harrison, and Mount (1993) found that in a chinchilla, the inner hair cells were 
preferentially damaged.  Therefore, pathophysiological differences across animal species 
might exist.   
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Vinka alkaloids.  Vinka alkaloids make up a group of products: vinblastine, 
vincristine, and vinorelbine.  Vinblastine and vincristine are natural products derived 
from the periwinkle plant (Rybak et al., 2007).  
 Vinblastine blocks mitosis while also altering amino acid metabolism (Rybak et 
al., 2007).  Vinblastine is a cell cycle-specific drug for the M phase.  Vinblastine is used 
to treat breast carcinoma, choriocarcinoma, testicular germ cell carcinomas, bladder 
carcinoma, non-small cell lung carcinoma, carcinomas of the kidney, Hodgkin’s and non- 
Hodgkin’s lymphomas, Kaposi’s sarcoma, Letterer-Wiew disease, mycosis fungoides, 
metastatic malignant melanoma, and germ cell ovarian tumors (Rybak et al., 2007).  
 In rabbits, vinblastine was reported to destroy hair cells without having an effect 
on nerve fibers or spiral ganglion (Serafi & Hashash, 1982).  There has been only one 
human case where ototoxicity was reported with vinblastine (Moss, Hickman, & 
Harrison, 1999).  The patient was also receiving doxorubicin, bleomycin, and 
dacarbazine.  After each session, the patient reported tinnitus, which lasted 7-10 days.  A 
mild high-frequency hearing loss occurred in the patient but speech frequencies were not 
affected (Moss et al., 1999)    
 Vincristine is similar to vinblastine.  Vincristine treats various types of cancer. 
However, contrary to vinblastine, vincristine was shown to destroy sensory cells, spiral 
ganglion neurons, and their fibers in rabbits (Serafy & Hashash 1982).  Some cases 
reported hearing loss after receiving vincristine therapy.  Mahajan, Ikeda, Myers, and 
Baldini (1981) reported a case where a woman experienced two separate cases of 
temporary bilateral, severe (60 dB HL), sudden sensorineural hearing loss across all 
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conventional test frequencies following vincristine treatment.  After two months, hearing 
was restored in both cases following treatment with prednisone and cytosine arabinoside.   
 Vinorelbine is also a vinca alkaloid derived from vinblastine.  Non-small cell lung 
carcinoma and breast carcinoma are cancers vinorelbine has been used to treat.  Hearing 
loss was not a common side effect of vinorelbine (Rybak et al., 2007). 
Difluoromethylornithine.  Difluoromethylornithine (DFMO) is derived from the 
amino acid ornithine and is used for prevention and treatment of cancers and parasitic 
diseases (Rybak et al., 2007).  Meyskens and Gerner (1999) reported DFMO caused not 
only cochlear ototoxicity but the vestibular system could also be affected.  Creaven, 
Pendyala, and Petrelli (1993) as well as Horn, Schechter, and Marton (1987) found 
DFMO caused high frequency hearing loss but symptoms were reversible in most cases.  
However, Croghan, Aickin, and Meyskens (1991) reported hearing loss following DFMO 
therapy at 500, 1,000, 2,000, 4,000, and 8,000 Hz, while Meyskens, Kingsley, Glattke 
Loescher, and Booth (1986) reported a flat configuration hearing loss (all conventional 
test frequencies).  Patients undergoing DFMO treatment might present with atypical 
audiograms typically associated with ototoxicity.  Tinnitus was also a reported symptom 
(Creaven et al., 1993).  
Position Statements on Ototoxicity 
The American Speech-Language-Hearing Association (1994) released a position 
statement titled Audiologic Management of Individuals Receiving Cochleotoxic Drug 
Therapy.  According to this statement, testing higher frequencies above the conventional 
limit of 8,000 Hz allowed for earlier detection of ototoxic frequency shift.  It was 
recommended that patients be counseled on the potential ototoxic effects before 
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treatment, baseline testing be completed before drug administration, and follow-up 
monitoring sessions be completed as soon as possible following treatment.  Testing of 
fewer frequencies on patients who were too ill to complete an entire test was acceptable.  
The American Academy of Audiology (2009) released a position statement on 
ototoxic monitoring.  In this statement, the following two main goals of a program were 
stated:  
1. Early detection of changes to hearing status presumably attributed to a 
drug/treatment regime so that changes in the drug regimen may be considered, 
and 2. Audiologic intervention when handicapping hearing impairment has 
occurred). (p. 3)  
This type of program potentially provided prevention of hearing loss in 
frequencies essential to communication. When a hearing loss affected frequencies where 
speech sounds occurred, the correct intervention could be made so communication 
abilities remained successful.  This intervention included counseling on communication 
strategies, amplification, and assistive listening devices.  
Ototoxicity Monitoring 
The American Academy of Audiology (2009) recognized conventional and high 
frequency audiometry (HFA) as a successful approach to ototoxic monitoring.  Other 
methods discussed as successful approaches were conventional audiometry and 
otoacoustic emissions.  With each approach to ototoxicity monitoring, a baseline 
assessment needed to be obtained for comparison to follow-up evaluations.  Ideally, the 
baseline assessment included not only air-conducted, pure tone thresholds but also 
tympanometry and word recognition testing. 
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Fautsi et al. (1984) demonstrated the success of HFA in a study of 77 males 
receiving ototoxic medication.  Hearing threshold shifts were detected sooner using HFA 
when compared to conventional audiometry.  In HFA, a Hughson-Westlake (Hughson & 
Westlake, 1944) method is used in non-conventional audiometry test frequencies of 
9,000-20,000 Hz (Carhart & Jerger, 1959).  High frequency testing is a concern in non-
sound treated environments due to the increased interference of ambient noise.  However, 
Gordon, Phillips, Helt, Konrad-Martin, and Fausti (2005) demonstrated HFA was reliable 
in a hospital ward. 
Fausti et al. (1999) identified a sensitive region in the cochlea (SRO), which was 
essential to establish HFA monitoring.  The SRO was unique to each patient.  The 
researchers discovered five thresholds specific for each participant’s hearing capabilities 
that were most sensitive to changes in hearing due to ototoxicity.  In this method, the 
highest audible frequency where patient’s thresholds were ≤ 100 dB SPL was labeled as 
the reference frequency. The only frequencies that needed to be tested to have a 94% 
detection rate were the reference frequency and the next four frequencies below it in 
1/6th-octave steps.  With this method, there was a 94% detection rate when monitoring 
cisplatin-induced ototoxicity.  Obtaining conventional and high frequency thresholds was 
reported to take 20 to 25 minutes, whereas using the SRO method only took six to eight 
minutes.  By only using these five high frequency thresholds, time of testing was cut to 
less than one-third of the time used when conducting full-frequency testing.  This 
protocol could alleviate some of the time demands and cost barriers that prevented the 
acceptance of ototoxic monitoring programs (Fausti et al., 1999).  To increase reliability 
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and sensitivity, Fausti et al. (2003) proposed using the same reference frequency as used 
in the previous study along with the six lower, adjacent frequencies in 1/6th-octave steps.  
According to the American Academy of Audiology (2009), one of the main 
benefits of HFA in an ototoxic monitoring program is use of accepted criteria for an 
ototoxic shift in hearing loss.  The American Academy of Audiology referenced ASHA’s 
(1994) criteria for detecting an ototoxic shift when using HFA.  The American Speech-
Language-Hearing Association identified the criteria for a confirmed ototoxic shift in 
hearing sensitivity including a 10 dB shift in hearing sensitivity in two or more adjacent 
frequencies, a 20 dB shift at any one frequency, and a consecutive failure to respond at 
three adjacent frequencies where a response was present at baseline testing (this was 
included for HFA where thresholds might be approaching the limits of the equipment). 
After a shift is initially detected, it must be proven repeatable.  
Challenges in Ototoxicity 
Not all cancer centers have ototoxic monitoring programs in place and 
audiologists frequently encounter challenges when attempting to implement an ototoxic 
monitoring program.  Current National Comprehensive Cancer Network (2003) 
guidelines, which are followed by oncologists, do not include any form of ototoxic 
monitoring, suggesting many patients are not receiving any monitoring or management 
(Dille, McMillan, Helt, Konrad-Martin, & Jacobs, 2015).  Reasons for this did not appear 
to be addressed formally in the literature.  It appeared patient and physician factors made 
ototoxic monitoring programming challenging to implement.   
Patients receiving ototoxic treatments are undergoing those treatments because 
they have been diagnosed with a life-threatening disease, which negatively impacts their 
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physical well-being.  Cancer can be an overwhelming diagnosis and patients are often 
busy with multiple medical appointments required for ongoing treatment of the primary 
disorder and side effects of the chemotherapy treatment.  Requiring audiology 
appointments at a different clinical site might add to the scheduling, transportation, and 
cost burdens; a hearing evaluation might not be a top healthcare priority for the patient.  
Physicians might not see hearing monitoring as a healthcare priority or be familiar 
with the importance of auditory rehabilitation strategies and timelines.  Consequently, 
patients are not always informed of the potential for a hearing loss, not given the 
opportunity to have their hearing monitored, and indirectly are denied the potential 
benefits of early identification and intervention.  To have a successful program, the 
physician needs to believe in the importance of hearing health care and integrate hearing 
health care. Another potential problem with the implementation of an ototoxic monitoring 
program is coordinating with primary care physicians.  The success of an ototoxic 
program relies on referrals from the primary care physician.  A baseline test needs to be 
obtained before the patient’s first treatment.  The audiologist and the physician need to 
have a good relationship in order to make appropriate decisions with regard to the patient.  
Currently, ototoxic monitoring programs are yet to be mandated even though 
there is a wealth of information regarding their importance.  Financing these programs 
could also create a barrier for program implementation.  Ototoxic monitoring requires 
patient enrollment, patient and professional appointment time, and proper equipment to 
complete the specialized audiologic testing.  Recruiting physicians and finding funding 
for these services might be a challenge.  In cases of established ototoxic monitoring 
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programs, it appeared the medical, pharmacy and audiology staff worked together 
(usually within a hospital) to establish ototoxic monitoring protocols.   
Hearing Testing 
Ambient Noise 
To obtain a hearing threshold, a person has to respond to the softest level of sound 
he/she can perceive 50% of the time.  To accomplish this, the ambient noise (background 
noise) in the test environment must not interfere with or mask the test signal to obtain 
accurate results.  When ambient noise masks the test signal, elevated thresholds are  
recorded.  
The International Organization for Standardization (ISO; 2019) developed a series 
of standards in order to ensure that reliable hearing thresholds are obtained.  In ISO’s 
(2009) ISO 8252: Acoustics: Audiometric test methods, Part 1, maximum permissible 
ambient sound pressure levels were provided.  The American National Standards 
Institute’s (ANSI; 2013) ANSI S3.1-R2013 also specified the maximum permissible 
ambient sound levels for audiometric testing using supra-aural earphones, insert phones, 
and bone conductors.  It was recommended when measuring these levels that a type 1 
sound level meter with octave bands be used.  The maximum permissible ambient noise 
levels (MPANLs) for each organization are illustrated in Table 1.  Maximum permissible 
levels of ambient noise were not included above 8,000 Hz due to the lack of information 
of attenuation of ear phones at frequencies above 8,000 Hz and the effects of upward 
spread of masking on these frequencies (ANSI, 2013).  No ambient noise levels for inter-
octave frequencies were published in the literature.  
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Table 1 
 
Maximum Permissible Ambient Sound Levels in Decibels Sound Pressure Level 
 
 Octave Band Center Frequency 
Standard 500 Hz 1,000 Hz 2,000 Hz 4,000 Hz 8,000 Hz 
 
ISO 8253 
 
 
18 
 
20 
 
27 
 
34 
 
33 
ANSI S3.1-R2013 
Supra-Aural 
  
16 21 29 32 32 
ANSI S3.1-R2013 
Insert earphones  
45 42 44 45 51 
   
Automated Audiometry 
Georg von Békésy first introduced automated audiometry into the field of 
audiology in 1947.  Békésy created a method that used a self-recording threshold 
audiometer, which required the patient to hold a button down when they heard a signal 
and release it when they lost the perception of the signal.  This method of finding 
threshold was referred to as method of adjustment.  Today, automated audiometers are 
typically programmed to use the Hughson-Westlake threshold-seeking method (Hughson 
& Westlake, 1944).  In this method, the audiometer or computerized audiometer makes 
adjustments based on whether the patient correctly responds to a stimulus or lacks a 
response to a stimulus.  This method of limits hearing threshold approach can be 
accomplished by the patient pressing the appropriate button or tapping on a touchscreen 
device (Margolis & Morgan, 2008).  
Automated or computerized audiometry has been used to provide hearing 
screening, diagnostic, and intervention services at locations where access to hearing 
specialists are limited.  In a report by Windmill and Freeman (2013), the global shortage 
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of audiological services was emphasized with shortages not only occurring in low and 
middle-income countries. The computer-based approach allows for many people to 
receive services who typically would not.  One healthcare provider could oversee more 
people when automated audiometry is utilized.  Automated audiometry has typically been 
used to aid in mass industrial hearing screenings and in research (Margolis & Morgan, 
2008).  
The validity of automated audiometry was assessed by Mahomed, Swanepoel, 
Eikelboom, and Soer (2013) in a systematic review and meta-analysis.  Twenty-nine 
reports comparing automated audiometry to manual audiometry were analyzed to 
determine the validity of automated audiometry.  The researchers concluded no 
significant differences were seen in test-retest reliability between manual audiometry and 
automated audiometry.  Test-retest variability for automated audiometry was also within 
normal limits compared to the manual audiometry’s test-retest variability.  Researchers 
did note limited data were available on difficult-to-test populations such as children and 
individuals who are mentally handicapped; many studies only tested people with normal 
hearing.  
Brennan-Jones, Eikelboom, Swanepoel, Friedland, and Atlas (2016) tested 42 
participants using manual and automated audiometry.  The aim of this study was to 
eliminate bias and include participants with a range of hearing thresholds.  Participants 
were tested manually in a sound isolated room and then with the KUDU wave automated 
audiometry system in a non-sound-isolated environment.  Participants in this study 
presented diverse clinical conditions including sensorineural hearing loss, tinnitus, 
conductive hearing loss, otosclerosis, otitis media, acoustic neuromas, Ménière's disease, 
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benign paroxysmal positional vertigo, perforated tympanic membrane, Eustachian tube 
dysfunction, ototoxic hearing loss, skull base fracture, and unilateral hearing loss. The 
researchers found the difference in threshold between the two situations was low with 
86.5% of four frequency averages within 10 dB and 94.8% within 15 dB.  
Hearing Testing Outside a  
Sound Booth.  
Audiometric testing is completed in a sound isolated room in order to obtain valid 
thresholds in normal hearing individuals.  The sound booth helps to control for ambient 
noise levels.  However, new technology has recently allowed for audiometric testing 
outside of a sound-isolated room.  Williams (2010) found it was possible to conduct 
hearing testing in environments where ambient noise levels were not adequate by testing 
with the use of noise-excluding headsets.  However, an audiometer that is used with the 
headset needs to be calibrated to the noise-excluding headset and proper placement of the 
headset is important.  
Gordon et al. (2005) conducted a study to evaluate whether extended high 
frequency monitoring could be accomplished outside of a sound isolated room when 
using insert earphones.  Hearing thresholds obtained in a double walled sound booth 
using Koss circum-aural earphones were compared to thresholds obtained at bedside in a 
hospital ward.  The thresholds from the sound booth were used to identify the SRO (the 
highest frequency where a threshold was ≥100 dB SPL and the six adjacent lower 
frequencies in 1/6th-octave steps).  This SRO was used for comparisons of thresholds 
obtained outside of the sound booth.  Hearing testing was then repeated outside of the 
sound booth at the test frequencies in the SRO and at 2,000 Hz due to the increased risk 
of interfering ambient noise at that level.  A second test session was then completed two 
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hours to three days after completion of the first test session.  During the second session, 
the order of testing was reversed--hearing testing was first completed outside of the 
sound booth and then followed by testing in the sound booth at the SRO and 2,000 Hz. 
Researchers found no significant differences in high frequency thresholds obtained in the 
booth and in the ward.  Researchers noted the results indicated good test-retest reliability 
when obtaining serial audiograms in the same setting with the same transducer.  
However, if setting and transducer were changed, results needed to be interpreted with 
caution.  During each test outside of the sound booth, ambient noise levels were recorded 
using the A-weighted filter in the octave band range of 125-16,000 Hz.  The mean 
ambient noise levels from the test sessions are illustrated in Figure 1.  
Typically, octave band measurements are not A-weighted and cannot be directly 
compared to maximum permissible ambient noise measurements (MPANLs).  Konrad-
Martin, Reavis, McMillan, Helt, and Dille (2014) reported ambient noise levels in dB 
SPL for hearing testing conducted in Veterans’ Administration (VA) hospital wards.  
Table 2 extrapolates the values from Figure 7 of that publication (Konrad-Martin et al., 
2014).  
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Figure 1. Mean ambient noise levels (dBA) reported in Gordon et al. (2005). Graphic 
provided courtesy of Jane Gordon (personal correspondence). 
 
 
 
Table 2 
 
Extrapolated Mean Ambient Noise Levels in Decibels Sound Pressure Level Reported 
from Veterans’ Administration Hospital Ward Measurements 
 
 Ambient Noise Levels 
 
125 250 500 750 1,000 1,500 2,000 3,250 
Frequency Band (Hz) 46 43 40.0 36 34 34 36 29 
 Ambient Noise Levels 
 
4,000 5,000 6,350 8,000 10,000 12,500 16,000 
 
Frequency Band (Hz) 
29 28 26 25 27 28 28 
 
Note. Extrapolated from Konrad-Martin et al. (2014), Figure 7. Original data values are 
archived and unavailable (personal communication).  
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Creare Wireless Automated  
Hearing test system.  Engineers at Creare Inc. (2016) recently developed a 
wireless automated hearing test system (WAHTS; see Figure 2).  This system was 
developed to permit audiometric threshold testing in atypical settings outside of a 
conventional sound booth (Meinke, Norris, Flynn, & Clavier, 2017).  This system was 
developed to  
(1) maximize passive attenuation, while keeping the headset comfortable enough 
to wear for the duration of a typical hearing exam, (2) leverage mobile 
technologies and eliminate cables, and (3) meet ANSI S3.6 and IEC 60645-1 
standards for audiometers. (Meinke et al., 2017, Instrumentation)  
The system includes a supra-aural headset that is operated in congruence with a tablet. 
The ear cups on the headset are lined with polyurethane foam.  The right ear cup contains 
a wireless audiometer circuit and the left ear cup contains a rechargeable lithium ion 
battery.  A speaker is mounted in a plastic faceplate covered in fabric.  This allows for the 
stimulus to be presented.  Overall, the headset is relatively large, stiff, and somewhat 
heavy in order to provide passive attenuation.  The headband in the system uses 
frictionless fit to enable quick placement of the WAHTS.  The frictionless fit also allows 
the WAHTS to hold its position on the listener’s ears.  The WAHTS supports a 4.0+ 
Bluetooth Low Energy interface.  This allows the device to be connected to a 
computerized tablet, which initiates the automated threshold test and receives the results 
through an application called TabSINT.  This application allows for customized tests and 
questionnaires to be administered on an array of mobile devices.  
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Figure 2. Creare wireless automated hearing test system including iPad. 
 
 
Meinke et al. (2017) conducted a study to characterize the Creare (2016) WAHTS 
performance in an occupational setting when administered by untrained personnel.  A 
within-subject repeated measures design study was completed to compare air-conducted 
threshold testing (500 to 8,000 Hz) obtained by untrained operators using the WAHTS in 
worksite conference rooms to test results obtained using computerized CCA-200 
audiometers in a mobile trailer sound booth by a trained tester.  Twenty workers were 
tested twice with the WAHTS in the conference room and once with the CCA-200 in the 
mobile trailer.  Mean thresholds obtained with the WAHTS were equivalent to mean 
thresholds obtained from the mobile trailer at 1,000, 2,000, and 3,000 Hz.  Thresholds 
were within 5 dB at 500, 4,000, 6,000, and 8,000 Hz.  Test-retest reliability results 
showed the Creare wireless headset system was equivalent to or better than previously 
reported ranges obtained by traditional equipment.  The ambient noise levels recorded in 
the rooms outside of the sound booth did not meet the ANSI (2013) standard for 
maximum permissible ambient noise for audiometric testing.  However, test-retest 
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average differences at frequencies up to 8,000 Hz were less than 1 dB and 1.1 dB at 8,000 
Hz.  It was important to note this was better than what was obtained in a sound booth 
with insert or TDH-39 supra-aural earphones (Swanepoel, Mngemane, Molemong, 
Mkwanazi, & Tutshini, 2010).   
Meinke et al. (2017) also found the Creare (2016) wireless headset provided 
attenuation to low frequency ambient noise equivalent to a “mini” single-walled sound 
booth.  These results suggested the WAHTS is a useful device for obtaining valid 
thresholds in diverse test locations without the use of a sound isolated test room and 
hearing thresholds could be obtained by an untrained operator.       
At the completion of the audiometric testing (Meinke et al., 2017), the WAHTS 
(Creare Inc., 2016) operator and the listener both took a survey on the tablets in order for 
the researchers to gain subjective data on the overall experience and usability of the 
device.  The operator survey included 18 statements that required a 7-point Likert-type 
scale response (1 = Strongly Disagree, 2 = Disagree, 3 =Somewhat Disagree, 4 = Neither 
Agree or Disagree, 5 =Somewhat Agree, 6 = Agree, and 7=Strongly Agree).  One open-
ended question was also included for additional comments related to the WAHTS.  
Listeners responded to eight statements on the same Likert-type scale listed for the 
operators.  Listeners also had the chance to provide additional opinions on the WAHTS.  
Overall, operators who were unfamiliar with the technology felt the device was easy to 
use, intuitive, did not require practice to operate it, and they said they would use this 
device if they had access to it. Similarly, listeners also had an overall positive response to 
the device.  Listeners felt subjectively that the testing with the WAHTS was just as 
accurate as the test in the trailer with the sound treated booths.  However, some listeners 
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commented they needed eyeglasses to view the tablet and one listener said he/she could 
not close his/her eyes during testing, which resulted with him/her being visually 
distracted.  Some listeners felt the test took longer with the WAHTS than in the mobile 
trailer, which was most likely due to the multiple tests on each ear being conducted to 
assess the reliability of the WAHTS (Meinke et al., 2017).   
Recent Advances in Ototoxicity Monitoring 
Rieke et al. (2017) proposed a new method for evaluating ototoxicity--a Békésy 
(1947)-style fixed-level frequency-threshold (FLFT).  This approach allows the listener 
to vary frequency at a fixed presentation level rather than having the listener vary the 
sound level.  By quickly sweeping through the frequencies at 80 dB SPL, the highest 
audible frequency is quickly determined.  Rieke and colleagues compared the FLFT to a 
modified SRO (limited output at 80 dB SPL), which was the commonly accepted method 
used to monitor ototoxicity.  Participants in the study had to have normal hearing in the 
conventional frequency range.  All patients were between the ages of 23 and 35 years. 
Each subject attended at least four different sessions.  During the first session, all subjects 
were trained on the Békésy tracking procedure.  Hearing thresholds were obtained at 0.5, 
1, 2, 3, 4, 6, 8, 9, 10, 11.2, 12.5, 14, 16, 18, and 20,000 Hz.  The stimulus was a pulsed 
pure tone that would start at 40 dB SPL and decrease in 4 dB step sizes.  Subjects would 
hold a response button until they no longer heard the tone.  The tone intensity would then 
increase again.  After the second reversal, the step size decreased to 2 dB.  The Békésy-
style fixed frequency audiometry (FFA) was then used to find the threshold at each 
frequency.  The SRO FFA frequencies were calculated by determining the uppermost 
frequency at which the subject had a valid threshold and the six adjacent lower 
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frequencies in 1/6th-octave steps.  The upper SPL limit was not set in advance for this 
study in order to determine the highest frequency in the SRO.  Any threshold within the 
allowable limits of the hardware was accepted (up to 111 dB SPL).  In all subsequent test 
sessions, thresholds were only obtained in the individualized SRO using FFA.  The FLFT 
was also obtained at each session.   
The FLFT method was adapted from Békésy’s (1947) method of adjustment 
threshold testing.  Contrary to Békésy’s original method, the FLFT stayed at the same 
intensity level and switched frequencies.  Listeners pressed a button when they could hear 
the frequency and released it when they could no longer detect the frequency.  The 
frequency level then decreased to lower frequencies until listeners pressed the button, 
again signaling they could detect a sound again.  The highest audible frequency was then 
labeled as the average over a certain amount of reversals.  In the current study, the 
average of the last six reversals was averaged with the first two being excluded.  Stimulus 
presentations started at 80 dB SPL at 8,000 Hz with pulsed tones extending up to 20,000 
Hz.  The initial frequency step-size was 1/6th-octave steps.  At the first reversal, the 
frequency step-size changed to 1/12th-octave steps.  Figure 3 is the trace of an FLFT test 
obtained during the present study.  
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Figure 3. Sample fixed-level frequency test tracing for Subject 608. 
 
The FLFT was evaluated in terms of repeatability, timing, and accuracy compared 
to the SRO.  It was concluded the FLFT and the FFA SRO were both highly repeatable, 
fast, and accurate.  Subjects served as their own controls because thresholds were 
compared to baseline. Subjects were not expected to have any hearing changes so this 
study did not look at sensitivity of the FLFT.  To evaluate reliability, intra- and 
intersession variability was calculated using the root mean square difference from the 
baseline SRO thresholds and FLFT.  To evaluate the repeatability, a single factor 
repeated measures ANOVA was used to evaluate learning effects over time.  After 
analysis, no learning effects were shown.  The SRO FFA took approximately 4.5 minutes 
and the FLFT took approximately 30 seconds to complete--a drastic decrease in test time 
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when compared to conventional audiometry (a reduction of 98%).  The FLFT directly 
translated to the SRO, suggesting the FLFT could be used to evaluate ototoxicity in 
patients.  Due to the suprathreshold testing, an additional benefit to the FLFT was the 
practicality of testing outside of a sound isolated room.  These advances might afford an 
opportunity to overcome the challenges that currently limit the implementation of 
ototoxicity monitoring programs and create an opportunity for more cancer patients to 
reap the benefits of early detection and intervention for ototoxicity.  
The Value of Ototoxic Monitoring 
Due to advances in science, survival rates have improved for people diagnosed 
with cancer.  More people are living in remission, which has led to an increased number 
of people who are living with the long-term side effects of the treatment they received.  
In many cases, the hearing loss acquired due to ototoxicity of various forms of cancer 
treatment lasted past the final treatment.  It was important to understand what effect 
living with an acquired hearing loss could have on a person in remission.  In general, 
hearing loss could have negative effects on people beyond the sensory deficit. 
Uncorrected hearing loss could potentially lead to reduced quality of life and social 
activity along with increased isolation and depression (Arlinger, 2003).  Lin et al. (2013) 
found hearing loss accelerated cognitive decline and incidence of cognitive impairment in 
elderly adults.  
Chia et al. (2007) assessed quality of life in relation to hearing loss.  Participants 
were given the Short Form Health Survey (SF-36; Ware, Kosinski, & Keller, 1994), 
which is a quality of life assessment that has eight subscales that represent dimensions of 
health and well-being: physical functioning, role limitations due to physical problems, 
34 
 
 
 
bodily pain, general health perceptions, vitality, social functioning, role limitations due to 
emotional problems, and mental health.  Participants received a hearing assessment, 
which included an interview about perceived hearing loss, and air and bone conduction 
threshold testing at traditional test frequencies.  Factor analysis, Australian normalized 
scores, Mantel-Henzsel chi-square statistic with 1 degree of freedom, t-tests, and F-
statistic were used to analyze the data in this study.  Participants with bilateral hearing 
loss scored lower on the SF-36 in comparison to participants with unilateral hearing loss. 
People with mild bilateral hearing loss scored lower on the SF-36 than those with normal 
hearing (Chia et al., 2007).   
Similar findings in older adults were reported by Dalton et al. (2002) who 
conducted a study comparing quality of life to hearing loss.  Dalton et al. used the 
Hearing Handicap Inventory for the Elderly-Screening (Ventry & Weinstein, 1982) along 
with additional hearing related communication difficulty questions to assess quality of 
life.  People with hearing loss had decreased scores in every domain of the Hearing 
Handicap Inventory for the Elderly-Screening version.  Severity of hearing loss was 
directly related to self-reported communication difficulties as well as lower scores on 
both the Mental Component Summary score and the Physical Component Summary score 
of the SF-36 (Dalton et al., 2002). 
People who have a close relationship with a person with a hearing loss might also 
be negatively affected.  In a study conducted by the National Council on Aging in the 
United States (Seniors Research Group, 1999), the researchers compared people with 
longstanding hearing loss who wore hearing aids and those who did not in relation to 
quality of life.  The researchers also gave the participants’ significant others a 
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questionnaire to assess the significant other’s well-being.  People with untreated hearing 
loss reported feeling sad or depressed more often as well as worried and paranoid.  
People with untreated hearing loss also took part in less social activity and had more 
emotional turmoil.  This also corresponded with the spouse’s response. When comparing 
the results of the people who wore amplification, their significant others often reported 
even more benefit than the person with the hearing loss in terms of the relationship at 
home, confidence, and other relationships (Seniors Research Group, 1999).  
Gruney et al. (2007) evaluated quality of life in relation to hearing loss caused by 
drug treatment in children who had neuroblastoma.  One objective of Gruney et al. was to 
assess hearing loss and parent-reported psychosocial difficulties for the child after 
treatment.  The Pediatric Quality of Life Inventory 4.0 (Varni, 2019) was used to assess 
quality of life in the children.  Neuroblastoma survivors with hearing loss had a mean 
score of 10-points lower on the Pediatric Quality of Life Inventory 4.0.  Researchers 
concluded neuroblastoma survivors with hearing loss had an elevated risk for 
psychosocial difficulties (Gruney et al., 2007)   
When hearing loss is rehabilitated through amplification, there are potential 
improvements to quality of life.  Chia et al. (2007) found people who habitually wore 
hearing aids had better physical functioning on average.  In a meta-analysis, Chisolm et 
al. (2007) analyzed 16 studies where the researchers looked at quality of life in relation to 
hearing loss rehabilitation with hearing aids.  Research included in this study had 
information on non-acoustic benefits from amplification such as emotional well-being, 
stress levels, relationships, loneliness, and self-efficacy (Chisolm et al., 2007).  Chisolm 
et al. also concluded that hearing aids decreased negative psychosocial, social, and 
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emotional effects in people with hearing loss.  The authors also reported hearing loss 
could be a “potentially devastating chronic health condition if left unmanaged” (Chisolm 
et al., 2007, p. 169).  
Properly informing patients about the possibility of hearing loss as a side effect of 
the drug they are being exposed to could potentially reduce the negative impacts hearing 
loss has on quality of life if they are identified and treated early.  If patients are made 
aware of the possibility of side effects, they would potentially realize the hearing loss 
earlier by having their hearing status evaluated and be able to seek rehabilitation, thus 
retaining a better quality of life.  If the patient is receiving audiological services, a shift in 
hearing might be noticed before the negative effects of a hearing loss are noticed by the 
patient. When this occurs, the physician might be contacted and a different drug regimen 
might be suggested to reduce the drug’s impact on the auditory system.  
Rationale for Study 
Hospital-based cancer care centers in northern Colorado administer 
chemotherapeutics to patients that have the potential to be ototoxic.  These hospitals do 
not currently have an ototoxic monitoring program due to the lack of audiological test 
facilities and personnel. The hospital-based cancer treatment setting presents a unique 
opportunity to implement novel hearing testing technology and test protocols that might 
provide earlier identification of hearing loss or reinforce the need for audiological 
rehabilitation in cancer patients.  This study evaluated the use of the WAHTS (Creare, 
2016) to test the hearing of patients when operated by nursing staff at two hospital-based 
cancer treatment centers in northern Colorado.  
37 
 
 
 
 
 
 
 
 
CHAPTER III 
 
 
METHODS 
 
 
This study was designed to evaluate the use of Creare Inc.’s (2016) wireless 
automated hearing test system (WAHTS) in two cancer treatment centers when operated 
by untrained nursing staff.  In addition, the study compared the hearing test outcomes for 
the fixed-level frequency test (FFLT) and automated high frequency audiometry (AHFA) 
in terms of the identification of the highest audible frequency (HAF). 
Participants 
Participants in this study consisted of listeners who were undergoing cancer 
treatment and untrained nurse operators who administered the hearing testing.  Listeners 
and operators were recruited from two outpatient cancer treatment centers.  The study 
exclusion criterion included the following: formally trained in audiometry.  The research 
was conducted under the University of Northern Colorado’s Institutional Review Board’s 
(IRB) protocol (see Appendix A for approval).   
Listeners 
Study inclusion criteria included the following:  
• Be an adult over the age of 18 years 
• Be receiving chemotherapy with either carboplatin or cisplatin 
• Understand, speak, and read English 
• Have sufficient vision to view the tablet computer 
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• Have sufficient dexterity to be able to tap on the on-screen box displayed on 
the tablet computer. 
Study exclusion criteria included the following: 
• Have a cochlear implant 
• Have any medical condition of the ear that prevents use of the wireless 
headset such as a draining ear 
• Have any head injuries, surgical incisions or wounds 
• Are too febrile to participate in the hearing testing per nursing judgment. 
Operators 
Study inclusion criteria included the following:  
• Be employed as hospital/cancer center nursing staff  
• Understand, speak, and read English 
• Have sufficient vision to view the tablet computer 
• Have sufficient dexterity to be able to follow on-screen instructions to 
operate the computer tablet and place the wireless earphones on the listener. 
Instrumentation 
Creare Wireless Automated Hearing  
Test System 
  Creare Inc.’s (2016) wireless automated hearing test system (WAHTS) was used 
to obtain hearing sensitivity information.  The WAHTS was used to obtain the AHFA 
and the FLFT.  Both audiological tests determined the highest audible frequency a person 
could hear.  To measure hearing responses for AHFA, the WAHTS used an algorithm 
based on a modified version of the Hughson-Westlake procedure (Carhart & Jerger, 
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1959).  The WAHTS also used an algorithm to perform a Békésy-like (Békésy, 1947) 
FLFT technique.  
Order of administration of the AHFA and the FLFT was counter-balanced along 
with the starting test ear.  For AHFA, thresholds were identified at each test frequency 
(1,000, 2,000, 3,000, 4,000, 6,000, 8,000, 9,000, 10,000, 11,200, 12,500, 14,000, 16,000, 
18,000, 20,000).  The HAF was selected based on the highest audible frequency for 
which a person had a measurable threshold.  Thresholds could be as high as the output of 
the WAHTS at each frequency.  
For the FLFT testing, a tone was presented at 80 dB SPL at 8,000 Hz. The 
frequency of the tone gradually increased in 1/6th-octaves until the patient could no 
longer detect the tone.  The frequency then decreased until the patient detected the tone. 
After the first reversal, the step size was 1/12th-octave. The highest audible frequency was 
calculated based on the average of the last six reversals, ignoring the first two reversals. 
This was the same FLFT method used by Rieke et al. (2017).  
Tablet 
The WAHTS (Creare Inc., 2016) system supported a Bluetooth low energy (4.0+) 
interface, which allowed it to be connected to a tablet.  The tablet initiated the testing 
using an application (app) developed by Creare Inc. (2016) called TabSINT (v1.7.4). The 
TabSINT allowed the researcher to administer customized tests and questionnaires.  This 
app allowed the WAHTS to be connected to the tablet (Shapiro & Galloza, 2016). 
Subject identifiers were inputted into the app.  After data import was complete, the 
researcher was instructed to give the tablet to the hearing test operator.  The operator was 
instructed to place the WAHTS on the listener’s head and hand the iPad to the listener. 
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The app screen then displayed a large touchscreen box the listener touched to respond to 
the stimulus for each test.      
Sound Level Meter 
A Quest Type 2 SLM, Model 2700 (serial # HU2040042; Pine Environmental, 
2019a) with an OB-300 octave band analyzer (serial # HW3050014; Multimedia, n.d.) 
was used to obtain pre- and post-test ambient noise measurements.  Prior to each pre-test 
measurement, the SLM was calibrated using a Quest Model QC-10/QC-20 Acoustic 
Calibrator (serial # QIE010076; Lesman Instrument Co., 2019) to assure the SLM was in 
accordance with ANSI’s (1983) specifications for sound level meters. 
Survey Instrument 
Operators and listeners each completed a survey created in Qualtrics.  A 7-point 
Likert-type response was used in both the operator and listener survey: (1 = Strongly 
Disagree, 2 = Disagree, 3 = Somewhat Disagree, 4 =Neither Agree or Disagree, 5 = 
Somewhat Agree, 6 = Agree, 7 = Strongly Agree).  The operator survey consisted of 17 
statements previously used in WAHTS studies related to operator characteristics and 
settings (see Appendix B).  The listener survey included 12 statements previously used in 
WAHTS studies as well as the inclusion of new statements specific to this population’s 
characteristics.  An additional open-ended question for comments related to usability and 
the experience with the WAHTS was also included at the conclusion of both operator and 
listener surveys.  Operator and listener surveys were completed on a Google Nexus 7 
Tablet (Asus, Taiwan).  Results were uploaded to a password-protected webserver. 
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Experimental Procedures 
 Following proper calibration of equipment and informed consent, pre-test ambient 
noise was measured using a Quest Type 2 SLM, Model 2900 (serial # HU2040042; Pine 
Environmental, 2019b).  Ambient noise measurements were obtained at 31.5, 63, 125, 
250, 500, 1,000, 2,000, 4,000, 8,000, and 16,000 Hz.  Measurements took place within a 
two-foot circumference of the listener’s head.  Measurements were completed before and 
after the audiometric testing. 
 After the completion of data entry of alpha-numerical subject numbers and 
demographic details (age and gender), the tablet was handed to the nurse operator.  The 
operator followed on-screen directions to prep the listener and place the WAHTS (Creare 
Inc., 2016) on the listener’s head and handed the tablet to the listener.  The listener was 
instructed by the researcher and by reading text on the tablet regarding the steps to 
complete the AHFA and FLFT hearing tests in each ear.  Each test was timed through the 
TabSint (Creare Inc., 2016) app.  Post-test ambient noise levels were measured and data 
entered in the same method as pre-test ambient noise levels.  At the completion of the 
testing, the operator and listener took the usability survey. 
Data Analysis 
 To determine if the WAHTS (Creare Inc., 2016) could feasibly be implemented 
into outpatient cancer centers, user/operator surveys were descriptively analyzed (see 
Appendices B and C). Mean pre- and post-test ambient noise levels were analyzed and 
compared for the two test sites.  Attenuation of the WAHTS in relation to the average 
ambient noise level was compared at each frequency band. Listener/operator surveys and 
ambient noise levels were imported from the database into Excel.  All data were analyzed 
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in Excel.  A Wilcoxon (1945) signed ranks test was used to evaluate differences between 
the highest audible frequency identified by the FLFT and the AHFA.  A Student’s t-test 
was used to evaluate the testing time differences between the AHFA and the FLFT 
audiological tests. 
.  
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CHAPTER IV 
 
 
RESULTS 
  
 
 Participants were recruited and data were collected in accordance with an 
approved IRB executed by the University of Northern Colorado (see Appendix A) and a 
reciprocal agreement from Banner Health’s IRB (see Appendix D).  
Test Environments 
Data collection took place in two outpatient cancer treatment centers in northern 
Colorado.  The chemotherapy clinics were set up to have multiple patients treated 
simultaneously in the same room.  Site 1 was set up in a “pod” design with a ratio of one 
nursing station to four patient chairs.  There were half walls separating patients from one 
another and from other “pods” (see Figure 4).  Site 2 was one large room with leather 
recliners lined up beside each other around the perimeter of the room.  There were no 
dividers between patients at Site 2 (see Figure 5).  A single nursing station was positioned 
so all patient chairs could be sight monitored.  The area where audiometric testing took 
place in each cancer center was based on where the listener subject was receiving 
treatment and locations were not pre-selected on the basis of room acoustics.  Listener 
and operator participants were recruited from the staff and patient populations at each test 
site as previously described in the methods section of Chapter III. 
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Figure 4.  Aerial diagram of chemotherapy treatment area at Site 1. 
 
 
 
 
 
 
Figure 5.  Aerial diagram of the chemotherapy treatment area at Site 2. 
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Participants 
 Study participants were comprised of both hearing test listeners (n = 21) and 
operators (n = 8).  
Listeners 
Listener participants included 21 patients being treated in one of two outpatient 
cancer treatment facilities. There were 9 males and 12 females.  The ages of listener 
participants ranged from 36 to 76 years with an average age of 60.2 years.  Seven 
participants were being treated with cisplatin and 14 were being treated with carboplatin. 
The most common cancer diagnosis being treated was ovarian (n = 5), followed by lung 
(n = 3), breast (n = 2), esophageal (n = 2), bladder (n = 1), endometrial (n = 1), 
endometrial/uterine (n = 1), kidney (n = 1), ovarian/colon (n = 1), pharynx (n = 1), and 
throat (n = 1).  Treatment cycles ranged from cycle 1 to cycle 22 with the majority falling 
within cycles 2-5.  Table 3 provides a summary of listener participants’ demographic and 
treatment information.  
Hearing testing occurred simultaneously while listeners were receiving 
chemotherapy or outpatient services such as fluid replacement due to cancer treatment. 
Eleven listeners were tested at Site 1 and 10 listeners were tested at Site 2.  All hearing 
tests were completed during routine operating hours of the clinics. 
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Table 3 
 
Demographic and Treatment Characteristics of Listener Participants 
 
Subject Sex Age (yrs.) Cancer Diagnosis Treatment Cycle 
Site 1      
1 M 56 Throat Cisplatin 2 
2 F 67 Ovarian  Carboplatin 22 
3 F 58 Breast Carboplatin 5 
4 M 56 Bladder Cisplatin 2 
5 M 70 Esophageal Cisplatin  4 
6 M 56 Esophageal Carboplatin 3 
7 F 46 Breast Carboplatin 5 
8 M 76 Liver Cisplatin  2 
9 F 50 Breast Carboplatin 1  
10 M 76 Lung Carboplatin 2 
11 M 60 Kidney Cisplatin 2 
      
Site 2      
12 F 56 Ovarian/Colon Carboplatin  4 
13 M 63 Lung Carboplatin 3 
14 F 68 Lung Carboplatin 3 
15 F 36 Ovarian Carboplatin 4 
16 F 65 Ovarian Cisplatin 2 
17 F 63 Ovarian Carboplatin 9 
18 F 53 Endometrial Carboplatin 3 
19 F 61 Endometrial/uterine Carboplatin 4 
20 F 78 Ovarian Carboplatin 4 
21 M 51 Pharynx Cisplatin 2 
M (SD) 60.2(10.4)    
 
 
Operators 
Eight registered nurses from Site 1 and Site 2 participated in this study as 
“operators” of the hearing test equipment.  All operators reported they had not given 
hearing tests before.  Operators were able to test multiple listener participants if the 
listener subject was on their caseload for chemotherapy treatment at the time of listener 
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recruitment. Table 4 provides a summary of operators and number of hearing tests given 
per operator.  
 
Table 4 
 
Operator Testing Session Summary 
 
Operator Subject Number Number of Listeners Tested 
Site 1  
1 1 
2 3 
3 2 
4 2 
5 3 
Site 2  
6 4 
7 2 
8 4 
 
Ambient Noise Levels 
One-third octave-band ambient noise level measurements were taken before and 
after hearing test data collection and are summarized in Table 5.
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Table 5 
Ambient Noise Level Measurements Taken Before and After Hearing Test Data Collection 
 
Overall  
Ambient 
Noise 
 
Octave Bands (Hz) 
(dB SPL) 
  
dBA 
 
31.5 63 125 250 500 1,000 2,000 4,000 8,000 16,000 
1 Pre 42  64 61 51 45 48 32b,c 30b 34b,c 25a,b,c 27 
1 Post 46  64 61 51 46 43b 44 46 39b,c 33b,c 28 
2 Pre 47  62 56 50 46 43b 43 39b 33b,c 35b,c 27 
2 Post 44  62 57 50 45 42b 38b 37b 39b,c 32a,b,c 28 
3 Pre 46  60 52 50 46 42b 33b,c 34b,c 36b,c 28a,b,c 28 
3 Post 54  61 55 52 48 41b 44 39b 32a,b,c 28a,b,c 27 
4 Pre 45  63 57 52 41 36b,c 35b,c 35b,c 38b,c 26a,b,c 29 
4 Post 45  64 56 54 48 47 35b,c 34b,c 30a,b,c 26a,b,c 27 
5 Pre 52  64 57 49 47 41b 37b,c 32b,c 27a,b,c 26a,b,c 27 
5 Post 54  64 57 50 45 40b 34b,c 38b 37b,c 29a,b,c 28 
6 Pre 58  60 63 54 50 43b 42b 34b,c 33b,c 29a,b,c 28 
6 Post 46  60 62 48 50 42b 34b,c 40b 39b,c 28a,b,c 27 
7 Pre 48  67 58 50 47 50 48 44b 44b,c 32a,b,c 27 
7 Post 43  66 59 50 46 39b 40b 33b,c 33b,c 28a,b,c 27 
8 Pre 49  64 57 49 49 39b 35b,c 35b,c 44b,c 32a,b,c 28 
8 Post 47  65 58 51 56 44b 38b 41b 39b,c 34b,c 27 
9 Pre 49  62 56 49 48 49 29b,c 31b,c 26a,b,c 25a,b,c 27 
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Table 5 Continued 
 
Overall  
Ambient 
Noise 
 
Octave Bands (Hz) 
(dB SPL) 
  
dBA 
 
31.5 63 125 250 500 1,000 2,000 4,000 8,000 16,000 
9 Post 47  66 58 49 49 37b,c 46 43b 34b,c 28a,b,c 28 
10 Pre 46  66 60 50 49 44b 38b 35b,c 38b,c 33b,c 28 
10 Post 60  67 61 51 45 42b 40b 37b 39b,c 31a,b,c 28 
11 Pre 39  64 46 49 40 34b 30b,c 39b 27a,b,c 25a,b,c 27 
11 Post 39  64 55 49 40 39 36b,c 30b 24a,b,c 25a,b,c 27 
12 Pre 45  60 49 47 47 43b 48 36b,c 35b,c 26a,b,c 27 
12 Post 49  56 45 46 47 41b 38b 37b 36b,c 25a,b,c 27 
13 Pre 54  58 50 59 57 54 55 44b 40b,c 32a,b,c 28 
13 Post 57  57 48 55 53 47 40b 49 36b,c 30a,b,c 28 
14Pre 48  51 48 53 50 50 38b 35b,c 41b,c 27a,b,c 29 
14 Post 49  50 49 46 48 43b 51 38b 35b,c 40b,c 28 
15 Pre 57  55 47 49 53 55 45 47 46 38b,c 28 
15 Post 52  58 50 48 51 66 49 56 39b,c 41b,c 28 
16 Pre 60  55 50 54 49 48 49 44b 53 37b,c 29 
16 Post 54  57 50 50 49 49 48 47 48b 42b,c 31 
17 Pre 45  56 53 48 50 44b 39b 36b,c 34b,c 25a,b,c 27 
17 Post 50  57 53 48 55 45b 46 47 40b,c 35b,c 28 
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Table 5 Continued 
 
Overall  
Ambient 
Noise 
 
Octave Bands (Hz) 
(dB SPL) 
  
dBA 
 
31.5 63 125 250 500 1,000 2,000 4,000 8,000 16,000 
18 Pre 46  52 48 46 44 45b 41b 42b 39b,c 27a,b,c 27 
18 Post 46  53 50 44 46 43b 43 41b 33b,c 26a,b,c 27 
19 Pre 43  50 48 46 44 43b 37b,c 38b 35b,c 27a,b,c 27 
19 Post 44  55 49 43 45 40b 40b 34b,c 33b,c 27a,b,c 27 
20 Pre 49  52 47 51 48 49 45 41b 34b,c 30a,b,c 27 
20 Post 52  54 48 48 49 48 43 40b 37b,c 33b,c 29 
21 Pre 59  56 47 49 52 52 46 39b 35b,c 36b,c 28 
21 Post 53  57 48 49 49 46 48 43b 36b,c 27a,b,c 28 
M 49  59 53 50 48 45b 41b 39b 36b,c 30b,c 28 
SD 5  5 5 3 4 6 6 6 6 5 1 
Range 39-60  50-67 45-62 43-59 38-57 34-66 29-55 30-56 24-53 25-42 27-31 
aLevel meets ANSI S3.1-1999 (R2013) criteria for testing from 250 to 8000 Hz with supra-aural earphones 
bLevel meets ANSI S3.1-1999 (R2013) criteria for testing from 250 to 8000 Hz with insert earphones  
cLevel meets the average attenuation values for WAHTS (Meinke, Norris, Flynn, & Clavier, 2017) 
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 A Student’s t-test (paired, two-tailed) was utilized to compare pre- and post-
ambient noise measurements at each octave band.  Using an alpha value of p = .05, there 
were significant differences between ambient noise levels at 63 Hz at Site 1 and 125 Hz 
at Site 2.  All other pre- and post-ambient noise levels were not significantly different. 
Because hearing test frequencies in this study were 1,000 to 20,000, the significantly 
different ambient noise levels at 63 and 125 Hz were not critical to analysis or practical in 
terms of determining the validity of hearing thresholds.  Therefore, pre- and post-test 
noise level measurements between the two sites were averaged together and mean values 
were used to compare the two test locations using a two-tailed unpaired Student’s t-test 
with an alpha value of p = .05.  There was a significant difference in the overall dBA 
value and for the octave-bands of 125, 8,000, and 16,000 Hz.  Table 6 provides all p-
values for ambient noise measurement comparisons.   
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Table 6 
Statistical Significance for Ambient Noise Measurement Comparisons 
 
 Site 1 Pre- and Post- 
Comparison 
 Site 2 Pre- and Post- 
Comparison 
 Site Combined 
Comparison 
Octave 
Band 
 
p-value 
 
p-value 
 
p-value 
dB C  0.10  0.26  0.00 
dB A  0.87  0.44  0.10 
31.5  0.07  0.40  0.00 
63  0.04  0.58  0.00 
125  0.71  0.01  0.18 
250  0.34  0.74  0.01 
500  0.57  0.41  0.00 
1,000  0.32  0.92  0.00 
2,000  0.25  0.09  0.00 
4,000  0.83  0.23  0.04 
8,000  0.65  0.36  0.09 
16,000  0.47  0.46  0.18 
Note: Significantly different (p> 0.05) ambient noise measurements are in boldface. 
 
Ambient noise levels were compared to ANSI (2013) maximum permissible 
ambient noise levels (MPANLs) for supra-aural and insert earphones when testing to 0 
dB HL.  The octave-band noise levels from both sites exceeded MPANLs throughout the 
frequency range for testing with supra-aural earphones. For insert earphones, the 
MPANLs were exceeded at 125-2,000 Hz.  However, ambient noise levels at 4,000 and 
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8,000 Hz were below specified maximum decibel levels. ANSI did not provide maximum 
permissible ambient noise levels for frequencies above 8,000 but recommended using the 
values for 8,000 Hz when considering higher test frequencies.  Following this 
recommendation; all ambient noise measurements at 16,000 Hz were within the 
maximum permissible ambient noise levels for insert earphones.  Compliance with ANSI 
MPANLs were summarized in Table 5. 
Ambient noise measurements were below the average attenuation levels for the 
WAHTS (Creare, 2016) for frequencies of 4,000 and above, permitting testing to 0 dB 
HL (Meinke et al., 2017).  Ambient noise was <5 dB above tolerances at 1,000-3,000 Hz, 
permitting testing to 5 dB HL.  The highest audible frequency data from both the AHFA 
and FLFT were all above 4,000 Hz.  Therefore, all thresholds used for analysis of highest 
audible frequency were valid.  
Figure 6 is an illustration of the mean ambient noise levels obtained at both 
research sites compared to attenuation of the WAHTS (Creare, 2016; Meinke et al., 
2017), ambient noise levels for VA hospital wards (Konrad-Martin et al., 2014) and 
MPANLs for supra-aural headphones according to ANSI (2013) criteria. 
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Figure 6.  Comparison of the wireless automated hearing tests system attenuation values 
for various test locations. 
 
Outcomes for Highest Audible Frequency 
 The WAHTS (Creare, 2016) was used to perform automated high frequency 
audiometry (AHFA) and the fixed-level frequency testing (FLFT).  The AHFA test 
yielded hearing thresholds measured at 1,000 to 20,000 Hz for 20 of the 21 listeners 
recruited for the study.  Subject 9 was unable to follow test instructions, which was most 
likely attributed to low cognitive ability reported by the nurse operator after the testing 
session.  Therefore, this subject was omitted from data analysis and outcomes were based 
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upon 20 listeners.  The highest audible frequency (HAF) used in analysis was the highest 
test frequency at which a valid hearing threshold could be measured using the two 
audiological test methods (AHFA and FLFT).  The highest audible hearing threshold 
obtained with AHFA was converted from dB HL to dB SPL for data analysis and test 
comparisons.  The FLFT measurement yielded a single frequency value, representing the 
highest audible frequency reported in Hz.  This frequency value was used for data 
analysis.  All thresholds for the highest audible frequency measured with FLFT were at 
80 dB SPL.  Table 7 includes summary data for both the AHFA and FLFT outcomes. 
Highest audible frequency differences were reported as AHFA minus FLFT.
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Table 7 
Automated High Frequency Audiometry and Fixed-Level Frequency Testing Outcome Summary 
  
 
Automated High Frequency 
Audiometry  
 
Fixed-Level Frequency Threshold 
 
Difference 
(AHFA-FLFT) 
Subject Ear 
 
dB SPL 
HAF 
(Hz) 
Test Time 
(sec) 
 
dB SPL HAF (Hz) 
Test Time 
(sec) 
 
dB Hz 
Time 
(sec) 
1 
R  90 4000  CNC 
 80 3175 
142 
 10 825 CNC 
L  95 8000  80 5138  15 2862 
              
2 R  70 11200 1192  80 12457 123  -10 1257 1069 
L  80 10000  80 11533  0 1533 
              
3 R  70 10000 1339  80 13325 122  -10 3325 1217 
L  65 10000  80 13982  -15 3982 
              
4 R  80 12500 1479  80 12699 152  0 199 1327 
L  80 12500  80 13584  0 1084 
              
5 R  90 9000 1909  80 7266 108  10 1734 1801 
L  75 6000  80 6727  -5 727 
              
6 R  75 14000 1230  80 14814 181  -5 814 1049 
L  75 12500  80 14945  -20 2445 
              
7 R  60 12500 1274  80 14672 211  -20 2172 1063 
L  55 12500  80 14117  -25 1617 
              
              
8 R  80 10000 1116  80 8156 241  0 1844 875 
 L  70 10000   80 8894   -10 1106  
  5
6
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Table 7 Continued 
  
 
Automated High Frequency 
Audiometry  
 
Fixed-Level Frequency Threshold 
 
Difference 
(AHFA-FLFT) 
Subject Ear 
 
dB SPL 
  HAF  
(Hz) 
Test Time 
(sec) 
 
dB SPL HAF (Hz) 
Test Time 
(sec) 
 
dB     Hz 
   Time    
(sec) 
10 
R  75 10000 
1386 
 80 5237 
           124 
 -5 4763 1262 
L  95 9000  80 5288  15 3712 
              
11 R  75 10000 2475  80 11423 76  -5 1423 2399 
L  70 10000  80 11986  -10 1986 
              
12 R  75 14000 1891  80 14254 138  -5 254 1753 
L  75 12500  80 14957  -5 2457 
              
13 R  75 10000 1429  80 10679 293*  -5 679 1136 
L  65 10000  80 11758  -15 1758 
              
14 R  80 10000 1514  80 6051 303  0 3949 1211 
L  90 9000  80 5879  10 3121 
              
15 R  75 14000 1207  80 15844 99  -5 1844 1108 
L  45 14000  80 13070  -35 930 
              
16 R  75 10000 1386  80 11533 100  -5 1533 1286 
L  95 8000  80 5391  15 2609 
              
17 R  80 10000 1424  80 10991 88  0 991 1336 
 L  80 10000   80 9514   0 486  
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Table 7 Continued 
  
 
Automated High Frequency 
Audiometry  
 
Fixed-Level Frequency Threshold 
 
Difference 
(AHFA-FLFT) 
Subject Ear 
 
dB SPL 
HAF 
(Hz) 
Test Time 
(sec) 
 
dB SPL HAF (Hz) 
Test Time 
(sec) 
 
dB Hz 
Time 
(sec) 
18 
R  75 12500 
1371 
 80 13982 
158 
 -5 1482 1213 
L  75 12500  80 14672  -5 2172 
              
19 R  85 12500 1375  80 10177 166  5 2323 1209 
L  80 12500  80 9514  0 2986 
              
20 R  95 9000 1746  80  6303** 127  20 1449 1619 
L  95 9000  80 5339  15 3661 
              
21 R  70 12500 1513  80 13505 88  -10 1005 1425 
L  80 12500  80 13716  0 1216 
M 
 
 
 
10705 1487  
 
10695 144.6  -3 1886.7 1335 
SD 
 
 
 
1916 323  
 
3600 57.3  11.5 1086.2 350 
Min 
 
 
 
4000 1116  
 
3175 76  -35 199 875 
Max 
 
 
 
14000 2475  
 
15844 303  20 4763 2399 
**Highest audible frequency was manually calculated with five frequency reversals instead of six due to software error on last reversal. 
### FLFT was higher than AHFA 
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Highest Audible Frequency  
Comparison 
The range of frequency differences between the AHFA and FLFT was 199-4,763 
Hz.  The mean difference in the highest audible frequency identified by each hearing test 
was 1,886.7 Hz with neither the AHFA nor FLFT consistently identifying the highest 
audible frequency higher or lower than the other.  Figure 7 provides a graphic illustration 
of the highest audible frequency identified by both test methods for each subject. 
A 2-tailed Wilcoxon signed ranks test was completed to compare the highest 
audible frequency identified by AHFA and FLFT automated test procedures.  There was 
no significant difference between the two test methods (p = 0.995). Therefore, the highest 
audible frequency elicited from the FLFT and AHFA is not statistically nor significantly 
different.  A Wilcoxon signed-ranks test was also utilized to further analyze ear 
differences in highest audible frequency.  In right ears, the difference in highest audible 
frequency was not statistically nor significantly different (p = 0.926).  The previous 
statement was also true for left ears (p = 0.911).  
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Influence of Stimulus Levels 
The single stimulus level during the FLFT (80 dB SPL) and variable stimulus 
levels available for measuring the highest audible frequency using AHFA likely 
contributed to some discrepancies between the highest audible frequencies identified 
between the two test methods.  In some test frequencies (125-9,000; 12,500; 16,000-
20000), output limits of the WAHTS (Creare, 2016) was ≥5 dB than the 80 dB SPL used 
in FLFT testing.  Therefore, a hearing threshold measured during AHFA could be higher 
than 80 dB SPL at these frequencies.  This could result in an over-estimation of highest 
audible frequency being reported for AHFA in comparison to the FLFT.  Contrarily, 
patients could also have an actual hearing threshold at the highest audible frequency 
during the AHFA testing that is below 80 dB SPL.  This could lead to the AHFA under-
estimating the HAF compared to the FLFT administered above the actual hearing 
threshold.  The majority of these discrepancies occurred between 75 and 80 dB SPL and 
likely reflected the test-retest variability (±5 dB) when measuring hearing thresholds in 
adults (Swanepoel et al., 2010).  Figure 8 illustrates the trends of over- and under-
estimating the highest audible frequency identified by each test method when referencing 
the threshold level for AHFA. 
In 100% of AHFA tests, where the hearing threshold level was 85-90 dB SPL, the 
HAF was an over-estimation of HAF identified in comparison to the FLFT.  When 
AHFA thresholds were between 45-75 dB SPL, the AHFA audiometry underestimated 
the HAF in 86% of tests.  
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Figure 8.  Trend in over- and under-estimation of highest audible frequency.  
Note. Formula used to calculate difference in HAF was AHFA HAF-FLFT HAF.  
 
Test Time Comparison 
Time was reported as the average time in seconds it took to complete the test.  
The mean test time for the automated AHFA was 1,487 seconds (24 minutes, 46.8 
seconds) and the mean test time for the FLFT was 144.6 seconds (2 minutes, 24.6 
seconds).  The mean difference in time was 1,317 seconds or 21 minutes, 57 seconds.  A 
one-tailed paired Student’s t-test was utilized to compare timing differences between 
 At 9000 Hz and below, the EHFA identified a higher HAF in comparison to 
the  
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AHFA and FLFT test time.  Utilizing a 95% confidence interval, the FLFT test time was 
significantly faster than the AHFA (p = 1.09414E-13).  
Survey Outcomes 
Listeners 
Twenty-one listener survey responses were collected at the conclusion of the 
audiometric testing and 20 were considered valid (Subject 9 omitted).  Listeners 
responded to twelve 7-point Likert scale statements.  A summary of survey responses is 
provided in Figure 9.   
The listeners provided 11 additional open-ended comments and feedback (see 
Table 8).  Overall, listener responses had a positive trend. The mean Likert score was 6.2 
out of seven.  Listeners thought the headset fit appropriately and comfortably and the 
tablet was easy to use.  Listeners also responded that having their hearing monitored 
during treatment was somewhat important (Likert = 5) to them and scheduling/traveling 
to multiple hearing appointments would be problematic for them (5.95 and 6.96, 
respectively).  The mean Likert score from listeners was a 4.9 on the statement related to 
being aware of the risk of hearing loss before treatment.  This value corresponded with 
the “somewhat agree” rating.  This was the lowest ranked statement for the listeners. 
Optional feedback provided by the listeners commonly reported that using the WAHTS 
was a more convenient option to have hearing monitored when compared to traditional 
ototoxic monitoring practices.  Some listeners were concerned about external noise and 
felt they might have confused IV pump beeps with presented beeps on the tablet. 
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Figure 9.  Listener survey responses (n = 20 
 
  
 
6.75
6.7
6.65
6.95
6.8
6.68
5.7
5.85
6.6
5.95
4.9
5
1 2 3 4 5 6 7
It was easy for the person to put the headset
on me.
The headset fit well and sealed my ears from
outside noise.
There was no discomfort during the
placement of the headset on my ears.
The headset felt stable on my head and did
not change postion (move) while taking the
hearing test.
The headset was not a problem to wear.
It was easy to press the button on the
computer tablet when I heard the sound.
The tablet computer made the hearing test
better.
Being provided a hearing test while receiving
chemotherapy was beneficial to me.
Traveling to get multiple hearing test during
chemotherapy would be problematic for me.
Scheduling to get multiple hearing tests
during chemotheraphy would be problematic
for me.
I knew the risk of hearing loss from
chemotherapy treatement before
participating in this study.
It is important to me to have my hearing
monitored during chemotherapy treatment.
Listener Survey Responses
Likert mean score
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Table 8 
 
Listener Additional Feedback and Comments 
  
Listener Comment  
1. Differentiating real life beeps from computer beeps was difficult at times. It 
was often difficult for me to actually differentiate between phantom beeps 
in my head. Either because I was hearing actual beeps or phantom beeps 
was hard to tell. On FLFT I know that often I still had my thumb on trigger 
when sound went out and I left it on the trigger for just a split second more 
just to make sure but in actuality my finger was on the trigger when I no 
longer could hear the sound. 
 
2. Neuropathy in the fingers had a slight affect on the touch pad. 
3. It’s a noisy environment. I’d like to have a comparative test at the end of 
chemo.         
4. This was much more convenient than going to another appointment and the 
test was simple to take. 
 
5. This was much more convenient than going to another appointment and the 
test was simple to take. 
 
6. Some of the tones were similar to the tones of the infusion machines, which 
could distract. 
 
7. The background noise made it a little difficult. I felt like I would have done 
better had it been quiet. 
 
8. It was very convenient to have it done here at the hospital. 
9. It was very easy and the headphones were comfy. 
10. It was a painless test. It was good because I knew I was going to have to get 
my hearing tested anyway and I think it would be beneficial for those of us 
getting this chemotherapy to know the amount of hearing loss and to see if 
there is someway to help prevent it in the future. 
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Operators 
  Twenty-one operator surveys were completed by eight different operators.  Two 
statements were reverse coded for consistency in directionality.  Figure 10 summarizes 
the tabulated scores.  In three surveys, operators left additional comments or feedback 
(see Table 9). 
 
  
Figure 10.  Operator survey response tabulated scores (n = 21).  
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The Wireless hearing test devices'
instructions are clear and easy to follow.
The wireless hearing test device is an
accurate way to measure hearing.
The wireless hearing test device is
complicated to use.*
The wireless hearing test device allows
you to identify which ear is being tested.
The headset was easy to place on the
listener.
The wireless technology stayed connected
during use.
The headset stayed in the proper position
during the hearing test.
The wireless hearing test software (app)
was intuitive.
The hearing test results were not
available to review.
The wireless hearing test system allows
me to monitor progess toware test…
The wireless headset fits the listener.
The headset visually appeared to seal the
ear adequately.
It takes practice to be able to use the
wireless hearing test system.*
General background noise in the room did
not interfere with the hearing test.
I would use the wireless hearing test
system if available to me.
Operator Survey Responses
Likert mean score
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Table 9 
 
Operator Additional Feedback and Comments 
 
Operator Comments  
1. Worried about the external noise that I was creating during the test for the 
patient. 
 
2. Hard to keep noise limited in the testing area. 
3. Patient reported the headset was a little too tight. 
 
Overall, operator responses showed a positive trend with mean Likert score of 5.5 
out of seven.  Operators reported the WAHTS (Creare, 2016) was easy to use, appeared 
to fit the listener well, and they would use the device if it was available to them.  In this 
study, operators did not manage the tablet throughout the duration of the testing due to 
other work responsibilities so responses to statements related to tablet functioning tended 
to indicate that operators neither agreed nor disagreed.  Additional feedback from nurses 
was commonly related to not being able to control the external noise.  
Summary of Outcomes 
The WAHTS (Creare, 2016) provided sufficient attenuation for ambient noise 
levels to permit valid hearing threshold testing in two outpatient chemotherapy centers 
that differed in room design and layout.  The highest audible frequencies obtained with 
the automated AHFA and FLFT tests were statistically compared and found to be 
comparable.  In terms of mean test time, the FLFT was significantly faster (1,868.9 
seconds or 31 minutes and 15 seconds faster) in comparison to the AHFA.  The operators 
and listeners responded favorably to the WAHTS technology when used in the outpatient 
chemotherapy settings.  Both AHFA and FLFT appeared to be valid test methods for 
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identifying the highest audible frequency by nursing staff for patients being treated in 
outpatient cancer treatment centers.  The FLFT might be preferable as a screening 
protocol due to the significantly faster test administration.   
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CHAPTER V 
 
 
DISCUSSION 
 
 
Ambient Noise 
Ambient noise was measured at two outpatient cancer treatment centers with 
different floor plans.  Site 1 was in ‘pod’ design where half walls surrounded the patient 
and Site 2 had an open layout with chairs lined up beside each other.  Sources of ambient 
noise were other patients talking nearby, nurses working in surrounding spaces, and IV 
pump alarms.  No heating, ventilation, and air conditioning systems were audible by the 
researcher but might have contributed to differences in low frequency ambient noise (63- 
and 125 Hz).   
Due to the level of ambient noise in the treatment centers, hearing thresholds 
could not be measured accurately to 0 dB HL across all test frequencies (250-20,000) 
with all transducers (insert earphones, supra-aural headphones, WAHTS; ANSI, 2013; 
Meinke et al., 2017).  Ambient noise has a greater effect on lower test frequencies. 
However, lower frequencies were not as critical for testing patients exposed to ototoxic 
chemotherapeutics.  This was due to the initial onset of the hearing loss typically 
beginning in the higher frequencies (Kopelman et al., 1988; Punnett et al., 2004). 
Therefore, in the limited sample of two out-patient centers, the attenuation of the 
WAHTS (Creare, 2016) allowed for accurate testing of thresholds down to 0 dB HL at 
4,000 Hz and above.  Thresholds were obtained at 5 dB HL for the test frequencies of 
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250-3,000 when using the WAHTS.  This was still sufficient for identifying an ototoxic 
threshold shift of 15 dB at a single frequency or 10 dB at adjacent frequencies as 
specified by ASHA (1994), especially since changes in threshold typically influence the 
higher test frequencies and older adults seldom have thresholds at 0 dB HL at all test 
frequencies.  
Testing could potentially be completed in exam rooms before chemotherapy 
treatment, especially if using the short-duration FLFT approach.  This would be of 
benefit to patients who have tinnitus or who are too distracted in the treatment 
environment and prefer a quieter listening environment.  Ambient noise levels in the 
exam rooms were not measured but were presumed to be lower in level due to isolation 
from other noise sources (patients, nursing staff, and medical equipment).  Patients were 
often seen in exam rooms prior to being moved to the treatment area so it would be 
feasible to have them take the hearing test at that time.  However, it would be important 
to have ambient noise measured before selecting which rooms would be best for 
audiological testing to take place and reconcile those levels with the WAHTS (Creare, 
2016) attenuation values.  
Extrapolated mean ambient noise levels from research at a VA hospital ward 
(Konrad-Martin et al., 2014) were lower in all frequencies in comparison to ambient 
noise levels from Site 1 and 2 in the current research.  Attenuation of the WAHTS 
(Creare, 2016) would allow for testing to 0 dB HL at 1,000-16,000 Hz in the VA hospital 
ward.  Potential causes of the lower mean ambient noise levels in the VA hospital ward 
were the testing being conducted in a room secluded from other patients and their 
families as well as nurses working on nearby patients.  However, specific test 
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environment information was not included in the methodology of the Konrad-Martin et 
al. (2014) study.  
One common concern voiced in the listener survey was interference between the 
IV pump monitors’ alarm tones with test stimuli presentations.  After becoming aware of 
this concern, the alert tones on the IV pumps were measured with a sound level meter. 
Thirty-second averages were sampled using dBA.  Ten measurements (five by each ear) 
were taken in the approximate location of where the patient’s ears would be during 
chemotherapy treatment.  The measurements were recorded as the “near ear” and the “far 
ear” with regard to physical placement of the IV equipment.  The maximum sound level 
for each sample was averaged to calculate the sound pressure level for the IV pump 
alarm.  This approach allowed for a more accurate representation of the alarm level 
because the breaks in between the alarm beeps would artificially reduce the average 
sound level of the alarm.  The average maximum sound level for the ear closest to the IV 
pump was 78.4 dBA and 77.0 dBA for the “far” ear.  Intermittent beeps of 77.0-78.4 dBA 
could have potentially artificially elevated thresholds and interfered with listener 
attention.  A trained operator or listener could pause the WAHTS (Creare, 2016) pending 
silencing the alarm.  Another potential solution to relieve this problem, which is currently 
being investigated by Creare (2016), would be to implement a sound level meter built 
into the headset that continually sampled ambient noise and automated software that 
temporarily paused testing when MPANLS were exceeded.  
Technology Implementation 
 Implementing the technology into the outpatient cancer centers presented certain 
challenges due to the characteristics of the environment as well as characteristics of the 
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test populations.  At both test locations, the tablet and headset dropped Bluetooth 
connection on multiple occasions and, occasionally, multiple times during a test session. 
Throughout testing, the tablet had to be reconnected to the headset at least one time for 
14 of the 20 participants and had to be reconnected five times for one participant.  Due to 
this technological difficulty, the researcher had to remain close to the subject during 
testing to be ready to troubleshoot connection issues.  Recently, Creare (2016) 
determined the dropped Bluetooth issue was a hardware bug for the Nexus tablet 
computer model used in this study and has been resolved with newer hardware releases 
by Nexus.    
Chemotherapy Patient Factors 
Written instructions were on the tablet for the listener subjects to follow.  
However, they often had to put on eyeglasses to be able to read the small print.  
Ramsdale and Charman (1989) reported the static response of the eye begins to decline at 
age 45; thus, the incidence of presbyopia increases after age 45 and the need of reading 
glasses increases.  The mean age of participants in the current capstone was 60 years so 
consequently, it was common for participants to require reading glasses to read the 
written instructions on the tablet.  This led to the headset having to be placed on 
participants’ heads multiple times throughout testing.  Testing would have been more 
seamless if recorded test instructions were built into the device in addition to the written 
instructions.  
 No patient was too ill to complete testing.  Overall, patients had a very positive 
response to the testing based on survey responses.  Patients who were being administered 
carboplatin were also commonly receiving taxol.  Benadryl could be effective in 
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counteracting the negative physical reactions from taxol (Carretta, Eisenhauer, & 
Rozencweig, 1997).  Depending on site protocol, patients either received Benadryl 
through an IV or took it orally at the time of treatment.  Patients and nurses often reported 
they would be unable to continue testing when the Benadryl began to take effect because 
of extreme drowsiness and being unable to stay awake for the testing.  On one occasion, a 
nurse had to delay the start of Benadryl administration so the participant could finish the 
hearing testing.  This situation would further justify the use of the FLFT method in terms 
of speed of testing. 
 Peripheral neuropathy is another side effect of taxol. Carretta et al. (1997) 
reported 80 of 151 patients being treated with taxol experienced neuropathy.  Peripheral 
neuropathy is also a side effect from cisplatin and carboplatin (Go & Adjei, 1999). 
Peripheral neuropathy could become an issue if patients were unable to feel if they were 
touching the tablet screen due to decreased tactile perception.  A physical button might be 
more appropriate in allowing biofeedback for patients with peripheral neuropathy 
symptoms in their fingers.  One subject in the current study verbally reported taxol-
induced peripheral neuropathy made it difficult to monitor how lightly or strongly to tap 
the screen when the sound was heard.  This subject completed the study without problem 
in spite of their concern.  
 Listener usability and comfort survey responses were in agreement with responses 
from Meinke et al. (2017).  This was an indication that patients undergoing cancer 
treatments did not have increased difficulty completing the hearing testing in comparison 
to people taking the hearing test in an occupational setting.  
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Implementing Fixed-Level Frequency Test and 
Automated High Frequency Audiometry in 
Ototoxicity Monitoring 
 A Wilcoxon signed ranks analysis demonstrated no statistical difference between 
the highest audible frequency measured by the AHFA and FLFT.  This result was in 
agreement with findings from Rieke and colleagues (2017) who tested the method on 
normal hearing younger adults.  Just as the highest audible frequency identified by FLFT 
directly translated to the SRO fixed frequency audiometry (FFA) in Rieke et al.’s 
research, there was no statistical difference between highest audible frequency identified 
by the AHFA and FLFT in the current study.  This study further extended the 
applicability of the FLFT administered with the WAHTS (Creare, 2016) outside of a 
sound-booth and demonstrated the practicality of administering the exam in two 
chemotherapy treatment centers.   
Ototoxicity monitoring relies upon the establishment of a sensitive region of 
ototoxicity as defined on a baseline audiogram and monitored throughout chemotherapy 
treatment.  Typically, the highest audible frequency at 100 dB HL and six lower 
frequencies are targeted for audiometric monitoring (Fausti et al., 1999).  The sensitivity 
and specificity of the FLFT for identifying a change in hearing status due to ototoxicity is 
unknown at this time.  The mean difference between the highest audible frequencies 
(HAF) identified between the AHFA (SRO approach) and the FLFT test methods was 
1,886.7 Hz, and the standard deviation was 1,086.2 Hz.  The clinical implication of an 
approximately 2,000 Hz error is most critical for the lower/speech frequencies when 
communication starts to be negatively impacted by chemotherapeutics.  If the FLFT 
under-estimated the highest audible frequency, which was used to define the SRO for 
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ototoxicity monitoring, the earliest shift in hearing status would potentially be missed or 
delayed in time.  If the FLFT over-estimated the highest audible frequency, it would fail 
to detect ototoxic effects occurring at lower frequencies.  It might be worthwhile to 
consider a higher output level (test level) for the FLFT that is more consistent with 
current audiometer output levels.  This would likely eliminate errors caused by the lower 
output limit of 80 dB HL implemented in the current version of the FLFT.     
 The FLFT was found to be much faster than the AHFA.  The mean time it took 
for the FLFT to be completed was 144.6 seconds (2 minutes, 24.6 seconds).  This was 
slower than the reported FLFT test time of ~30 seconds by Rieke et al. (2017).  This was 
possibly due to the testing taking place in a more distracting test environment, which 
might require more time to obtain six reversals on the Bekesy (1947) tracking.  The 
current study also evaluated the FLFT on subjects without normal hearing and receiving 
medication treatment, which might have influenced their level of alertness.  Nonetheless, 
the decreased test time in comparison to the AHFA has an advantage for patients and 
examiners.  Patients would spend less time testing so they would not need to schedule 
extra time for appointments or worry about the length of testing being challenging due to 
increased fatigue from side effects of the chemotherapy.  Examiners would spend less 
time administering the testing so more patients could be seen with no need for additional 
equipment or personnel to operate equipment.  In the current version, the FLFT might be 
well-suited as a quick ototoxicity screener, which might then be followed up with more 
extensive threshold testing in a controlled test environment if a shift in the highest 
audible frequency was detected.  
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Potential to Increase Patient Access to 
Ototoxicity Monitoring 
 
Operator Training 
Nurse operators who have had no specialized training in hearing testing could 
administer testing.  However, if nurses would be the only ones there to administer the 
testing, they would need more training on troubleshooting the device with regard to 
connection drops.  A mechanism would also have to be developed to transfer the test 
results to the audiologist for review, interpretation, and follow-up.  Training could be 
completed in one session held by the hearing healthcare professional who organized the 
program.  Nurses would be given an overview of the device and training on the software.  
 Survey responses obtained by nurses included concerns about outside noise in the 
cancer centers interfering with the hearing test.  In order to have nurses’ concerns be 
addressed, data would need to be presented to the nurses showing ambient noise levels 
were acceptable to produce valid hearing thresholds.  Nurse operator survey responses 
were also similar to operator survey responses from research in occupational hearing 
testing (Meinke et al., 2017).  Both groups of operators felt the device fit the listener’s 
ears well and would use it if available to them.  Therefore, the WAHTS (Creare, 2016) 
would likely be accepted in other treatment centers. 
Benefits of Ototoxicity Monitoring  
with the Wireless Automated  
Hearing Test System 
 
  Utilizing the WAHTS (Creare, 2016) to implement the FLFT has the potential to 
overcome barriers currently preventing the implementation of ototoxicity monitoring 
programs in the classic manner as reported by Konrad-Martin et al. (2017).  Because the 
WAHTS could be utilized in an outpatient treatment center, the hassle of scheduling 
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multiple appointments for the patient would be eliminated.  Consequentially, it would 
also require less time commitment.  Operators would not need to be trained in hearing 
testing so current staff could administer the testing with just one hearing healthcare 
provider reviewing the testing at an on-site or off-site location.  Nurses were used in the 
current study to administer the hearing testing but because operating the device did not 
require formal training, less highly paid support staff might be able to administer the 
testing.  The implementation of the WAHTS to administer the FLFT and/or the AHFA 
was feasible for both test sites.  No barriers were identified during the research study and 
both nurses and patients were supportive of its use.  Either the AHFA or the FLFT 
approach was feasible to implement using the WAHTS.  The advantage of the AHFA 
was the more detailed threshold data obtained with the testing and more information 
regarding ototoxic changes.  The disadvantage was the substantially longer test time.  As 
mentioned previously, the FLFT might be a useful screening tool to implement for 
ototoxicity monitoring.  To get an ototoxicity monitoring program functioning with the 
WAHTS in these settings, operating staff would need to complete a training session on 
the device and a plan would need to be developed with oncologists with regard to test 
choice, test protocol, and report/communication preferences with the audiologist.    
Strengths and Limitations 
 Testing was only completed in two outpatient cancer treatment centers.  However, 
the test environments were designed very differently from each other, which might 
permit generalization to a large number of outpatient chemotherapy centers.  The current 
study had a relatively small number of participants and was slightly lower in number to 
the Rieke et al. (2017) study (n = 29).  Recruiting patients was difficult because patients 
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were not receiving hearing results due to the experimental nature of the technology and 
test protocol.  Future studies that could actually implement an ototoxicity monitoring 
program and inform the patients of their hearing status would likely gain greater 
participation.  
 Ambient noise measurements were not done continuously throughout testing so 
they might not have captured when ambient noise levels were above the attenuation of 
the WAHTS (Creare, 2016) at specific test frequencies.  Meinke et al. (2017) 
recommended further research to implement and evaluate accuracy of in-ear microphones 
continuously measuring ambient noise levels and pausing testing when levels were too 
high to produce valid thresholds.  Additionally, the highest audible frequency using 
AHFA and FLFT was not compared to a gold-standard hearing test in a sound booth, 
which would have been ideal but impractical for this capstone research project.   
Future Research 
 Future research should implement the WAHTS (Creare, 2016) technology in a 
more diverse assortment of chemotherapy treatment centers with a larger population of 
participants.  Use of the FLFT and AHFA would need to be evaluated as part of a clinical 
research study that would implement a full ototoxicity monitoring program.  Future 
studies should also investigate whether the test needed to be nurse administered, support 
staff administered, or if the patient could self- administer the exam.  In this model, only 
one audiology professional would be required to supervise the program and 
review/interpret the test results.  Additionally, the audiologist would also be trained in 
troubleshooting the device and be on call for technology issues, similar to the way 
newborn hearing screening programs are implemented in hospital nurseries.   
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Conclusions 
 The WAHTS (Creare, 2016) provided sufficient attenuation of ambient noise and 
enabled valid hearing threshold measurements to 5 dB HL for 250-20,000 Hz in two 
outpatient chemotherapy treatment settings in northern Colorado.  There was no 
statistical difference in the highest audible frequency measured by the AHFA and FLFT 
test methods.  The FLFT required substantially shorter test times on average (24.78 
minutes versus 2.4 minutes).  Both the FLFT and AHFA administered via the WAHTS 
would be useful means of performing ototoxicity monitoring for patients receiving 
cisplatin and carboplatin treatments onsite in outpatient cancer treatment centers by 
untrained nursing staff. 
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CREARE WIRELESS HEADSET SYSTEM SURVEY FOR OPERATORS 
 
College of Natural and Health Sciences 
School of Human Sciences 
  
Operator Subject #___________  
  
Listener Subject #___________ 
  
Trial Number #_________ 
  
Headset Prototype_________ 
 
Wireless Headset Fit and Comfort SURVEYS: 
Thank you for helping with our research project. Below are a few brief questions to help us learn more about the new 
equipment we are developing for hearing testing. 
  
SECTION A: FOR LISTENERS 
The survey consists of a series of questions asking you to either rate statements from strongly disagree to strongly agree 
or fill in the blank. Your answers should reflect your feelings and opinions. Therefore, there are no right or wrong 
answers, so please answer honestly. The survey should take approximately 5-10 minutes to complete. (Note: this 
survey will be sized and adapted for proper display on the Tablet device). 
SECTION A: FOR MOBILE SCREENER OPERATOR  
1. Is this the first time you have performed a hearing test?                                                          YES                                 
NO  
2. If YES, have you previously received training on how to give a hearing test?                        YES                                 
NO 
3. What is your professional background? 
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Please circle the appropriate response (SD, D, N, A, SA) for each statement that best describes your 
feelings and/or opinions.  Please answer all questions and do not leave any blank. 
  
SD = Strongly Disagree    D = Disagree   SWD= Somewhat Disagree   N = Neither Agree or Disagree    SWA= 
Somewhat Agree   A = Agree    SA = Strongly Agree 
 
 
1. The wireless hearing test devices’ 
instructions are clear and easy to 
follow. 
SD D SWD N SWA A SA 
2. The wireless hearing test device is an 
accurate way to measure hearing. 
SD D SWD N SWA A SA 
3. The wireless hearing test device is 
complicated to use. 
SD D SWD N SWA A SA 
4. The wireless hearing test device allows 
you to identify which ear is being 
tested. 
SD D SWD N SWA A SA 
5. The headset was easy to place on the 
listener. 
SD D SWD N SWA A SA 
6. The wireless technology stayed 
connected during use. 
SD D SWD N SWA A SA 
7. The headset stayed in the proper 
position during the hearing test. 
SD D SWD N SWA A SA 
8. The wireless hearing test software 
(app) was intuitive. 
SD D SWD N SWA A SA 
9. The hearing test results were not 
available to review. 
SD D SWD N SWA A SA 
10
. 
The wireless hearing test system allows 
me to monitor progress toward test 
completion. 
SD D SWD N SWA A SA 
11
. 
The wireless headset fits the listener. SD D SWD N SWA A SA 
12
. 
The headset visually appeared to seal 
the ear adequately 
SD D SWD N SWA A SA 
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13
. 
It takes practice to be able to use the 
wireless hearing test system. 
SD D SWD N SWA A SA 
14
. 
General background noise in the room 
did not interfere with the hearing test. 
SD D SWD N SWA A SA 
15
. 
I would use this wireless hearing test 
system if available to me. 
SD D SWD N SWA A SA 
16
. 
Are there additional comments or feedback you can offer related to the use and functionality of this wireless 
test device? 
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CREARE WIRELESS HEADSET SYSTEM SURVEY FOR LISTENERS 
 
College of Natural and Health Sciences 
School of Human Sciences 
  
Operator Subject #___________  
 
Listener Subject #___________ 
 
Trial Number #_________ 
 
Headset Prototype_________ 
 
Wireless Headset Fit and Comfort SURVEYS: 
Thank you for helping with our research project. Below are a few brief questions to help us learn more about the new 
equipment we are developing for hearing testing. 
SECTION A: FOR LISTENERS 
The survey consists of a series of questions asking you to either rate statements from strongly disagree to strongly agree 
or fill in the blank. Your answers should reflect your feelings and opinions. Therefore, there are no right or wrong 
answers, so please answer honestly. The survey should take approximately 5-10 minutes to complete. (Note: this 
survey will be sized and adapted for proper display on the Tablet device). 
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Section A: FOR MOBILE SCREENER LISTENER 
Please circle the appropriate response (SD, D, N, A, SA) for each statement that best describes 
your feelings and/or opinions.  Please answer all questions and do not leave any blank. 
  
SD = Strongly Disagree    D = Disagree    SWD= Somewhat Disagree  N = Neither Agree or 
Disagree    SWA= Somewhat Agree  A = Agree    SA = Strongly Agree  
 
1. It was easy for the person to put the headset on me. SD D SWD N SWA A SA 
2. The headset fit well and sealed my ears from outside 
noise. 
SD D SWD N SWA A SA 
3. There was no discomfort during the placement of the 
headset on my ears.  
SD D SWD N SWA A SA 
4. The headset felt stable on my head and did not 
change position (move) while taking the hearing test. 
SD D SWD N SWA A SA 
5. The headset was not a problem to wear. SD D SWD N SWA A SA 
6. It was easy to press the button on the computer tablet 
when I heard a sound. 
SD D SWD N SWA A SA 
7. The tablet computer made the hearing test better. SD D SWD N SWA A SA 
8. Providing a hearing test while receiving 
chemotherapy was beneficial to me. 
SD D SWD N SWA A SA 
9. Traveling to get multiple hearing tests during 
chemotherapy would be problematic for me. 
 
SD D SWD N SWA A SA 
10. Scheduling to get multiple hearing tests during 
chemotherapy would be problematic for me. 
SD D SWD N SWA A SA 
11. I knew about risk of hearing loss from chemo 
treatment. 
SD D SWD N SWA A SA 
12. It is important to me to have my hearing monitored 
during chemotherapy treatment. 
SD D SWD N SWA A SA 
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13. Are there additional comments or feedback you can offer related to the use and functionality of this 
wireless test device? 
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